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Targeting Histone Modifications in Isocitrate Dehydrogenase-1 R132H Mutated Glioma and 
Oligodendrocyte Progenitor Cells  
 Lisa Sprinzen 
 
 Isocitrate Dehydrogenase-1 has been found to be mutated in over 70% of lower grade 
gliomas and has become an important diagnostic tool for tumor prognosis, however its role in 
glioma development, and its impact on response to therapy, is still not fully understood. 
Unmutated IDH1 functions to convert isocitrate to a-ketoglutarate (a-KG) in the tricarboxylic 
acid (TCA) cycle. Mutated IDH1R132H changes the enzymatic equilibrium and converts a-KG 
to 2-hydroxyglutarate (2-HG), an oncometabolite. IDH1R132H mutated tumors show an 
elevated production of 2-HG and epigenetic alterations in DNA and histone methylation. This 
mutation is predominantly seen in the proneural glioma subtype in which oligodendrocytes 
progenitors (OPCs) are considered the cell of origin due to phenotypic similarities. The effect of 
IDH1R132H mutation in cellular transformation has not been fully established. Epigenetic 
modifications connect genotype to phenotype by genetic expression alterations and epigenetic 
modifications are necessary for OPC differentiation. Tri-methylation of lysine residue K27 on 
histone H3 (H3K27me3) is a repressive mark associated with cell pluripotency. H3K27me3 is 




demethylases UTX/KMD6A and JMJD3/KDM6B. 2-HG is a competitive inhibitor of a-KG-
dependent demethylases, providing a mechanistic link between IDH mutations and increases 
H3K27me3 by inhibiting demethylation. In this thesis, we evaluated the epigenetic changes in 
mouse models of IDH mutant and wildtype glioma and genetically-transformed OPCs and tested 
the effects of drugs that target specific epigenetic marks. 
 We developed a mouse model of glioma to compare IDH1R132H cells to wildtype 
glioma cells and found that although there was no difference in survival, IDH1R132H gliomas 
have increased levels of 2-HG by MALDI-IMS and metabolomic analysis. Interestingly, based 
on RNA-sequencing analysis our IDH1R132H model has a more OPC-restricted expression 
profile compared the wildtype glioma model which have higher enrichment of genes from other 
cell lineages, including neurons, astrocytes, myelinating oligodendrocytes and microglia. We 
used the EZH2 inhibitor (Tazemetostat, EPZ-6438) and found that this treatment was not 
cytotoxic or cytostatic to our cells although H3K27me3 was reduced. Interestingly, Tazemetostat 
treatment increased the expression of non-OPC genes (genes normally expressed by other 
lineages as assessed using the Barres transcriptomic database). 
 To better understand how IDH1R132H influences OPC transformation, we transformed 
OPCs in vitro. OPCs were isolated from floxed p53 postnatal day 5 mice from and retrovirally 
infected with viruses to delete p53 alone or to also express IDH1R132H. OPCs that express 
IDH1R132H had increased levels of 2-HG by metabolomics and showed alteration in H2K27 
methylation and acetylation that resembled those seen in glioma cells. 
 Standard methods of western blot analysis consist of analyzing whole cell lysate, 
cytoplasmic and nuclear fractionation, or histone acid extraction. To analyze both the 




which cells were fractionated and the nuclear fraction was acid extracted. This method allows for 
the analysis of both cytoplasmic proteins as well as histone modifications by western blot.  Using 
this method, we found that treating glioma cells or OPCs with synthetic cell permeable octyl-
2HG, or expressing IDH1R132H, caused cells to have increased H3K27me3, while treatment 
with Tazemetostat caused a decrease in H3K27me3. Based on the RNA-sequencing data we 
found that increased H3K27me3 (ID1R132H mutation) express more OPC-like phenotype while 
reduced H3K27me3 (Tazemetostat treatment) induced an upregulation of genes associated with 
other lineages making them less restricted to the OPC transcriptional phenotype. We found that 
in both the glioma cells and OPCs, Tazemetostat treatment decreased H3K27me3 and increased 
H3K27ac.  
 Based on the increase of H3K27ac after Tazemetostat treatment, we hypothesized that a 
Histone deacetylase inhibitor (HDACi) would be synergistic. We found that although the 
HDACi Panobinostat was less cytotoxic to IDH1R132H mutated glioma cells and OPCs, co-
treatment with Tazemetostat is synergistic in mutant and wildtype models. We also saw that in 
IDH1R132H ex vivo slices, the co-treatment reduced tumor marker composition. These findings 
point to a novel therapeutic strategy for IDH1-mutated proneural gliomas that targets the specific 
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Chapter 1: Introduction 
 
1.1 Glioma Classification   
Gliomas are a type of brain tumor that arise from the glial cells in the central nervous 
system (CNS). To inform prognosis and guide treatment methods, brain tumors are categorized 
based on histological and molecular features. These are classified based on the specific glial 
lineage they resemble (i.e., astrocytic or oligodendroglial).  Subtypes and a numerical grading 
system are also used to grade gliomas histologically. The histopathological grading scale 
analyzes gliomas based on vascular proliferation, nuclear atypia, mitotic activity, and necrosis 12. 
Glioblastomas (GBM, WHO grade IV) are the most common and most aggressive type of 
primary brain tumor. GBMs histologically have necrosis and endothelial proliferation 13. 
Gliomas are a heterogenous disease that diffusely infiltrate the brain preventing complete 
surgical resection and obstructing treatments. 
GBMs are further classified as primary or secondary, based on the route of tumor 
progression. Primary GBM is the most common kind of brain tumor accounting for 45.6% of all 
primary malignant brain tumors 14. Primary GBMs form de novo without clinical or histologic 
evidence of a prior lower-grade lesion 8. These tumors mainly manifest in elderly patients and 
are thought to arise from rapid disease progression 15. Secondary GBMs develop through 
progression from lower grade lesions and affect younger patients 8,15. Although primary and 
secondary GBMs are histologically indistinguishable, many studies have shown evidence that 
they are actually distinct malignancies and harbor distinct genetic alterations.  Most notably, the 
majority of low-grade gliomas and secondary GBM have mutations in Isocitrate Dehydrogenase 
1 (IDH1).  This is discussed in more detail in the next section (1.2). 
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Secondary GBM develops from diffusely infiltrating low-grade gliomas. These tumors 
are classified based on the histological and transcriptional resemblance to normal glial cell types, 
i.e., astrocytes are astrocytomas and oligodenroglial are oligodendroglioma. These lesions are 
more common in younger patients and have a better survival rate than GBM with a median 
survival of 5 to 7 years compared to 15 months 16,17. At the time of diagnosis at early stages of 
disease progression, low-grade gliomas are less aggressive and slow growing, however they 
eventually progress to high-grade gliomas 17.  
1.2 Glioma, Genetic and Transcriptional Alterations 
Gliomas are diffusely infiltrating and have a heterogenous microenvironment preventing 
full surgical resection 18. This heterogeneity is found at the histological, transcriptional and 
genetic levels which are thought to cause poor prognosis  19.  To better understand gliomagenesis 
for patient prognosis, groups have used high-dimensional profiling studies examining gene 
expression and copy number alterations. The Cancer Genome Atlas (TCGA) was used to classify 
GBM as proneural, neural, classical, and mesenchymal (Table 1)  6,20. The proneural 
classification has a specific transcriptional signature with genes normally expressed in 
oligodendrocyte progenitor cells (OPC) 21-24. This finding has led to the hypothesis that OPCs are 
the cell of origin of proneural glioma. This is discussed in more detail in the next section (1.3). 
 Proneural gliomas are associated with specific genetic alterations, including Isocitrate 
Dehydrogenase (IDH1) mutations, Tumor Protein 53 (TP53) mutation and Platelet Derived 
Growth Factor Receptor Alpha (PDGFRa) amplification/mutation 6,25. Most secondary GBMs 
and over 75% of lower grade gliomas are classified as proneural 26. The other GBM subtypes 
account for the majority of primary GBM, are significantly less likely to harbor alterations in 
IDH1, TP53 or PDGFRa, but rather have Epidermal Growth Factor Receptor (EGFR) 
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amplification (95%) and loss of PTEN 6,26. Chromosome 7 amplification and Chromosome 10 
deletion are the most common chromosomal abnormalities in primary GBM but are less common 
in proneural glioma 6. The neural subtype expresses neuronal markers with a gene expression 
signature similar to normal brain that likely represents contamination of normal brain. More 
recently, single cell sequencing, has revealed that most IDH1-wildtype GBM contain a diversity 
of subtypes with mark variability in the relative abundance of these different glioma ‘states’   27-
31, while lower grade IDH1-mutated gliomas (WHO grade II and II astrocytomas and 
oligodendrogliomas) show more lineage-restricted phenotypes, with most glioma cells  




 These findings have led to a model that includes three different gliomagenesis pathways 
15,32,33. As previously described, primary GBM develops de novo (Figure 1.1). 
Oligodendrogliomas (Grade II) Progress to Anaplastic Oligodendrogliomas (Grade III) 
(Figure1.1). Astrocytomas (Grade II) grow into anaplastic astroctyomas (Grade III) and then to 
secondary high-grade GBM (Grade IV) (Figure 1.1).     
Glioblastoma 
Subtype 
Molecular Signatures Normal cell type 
resemblance 




Neural EGFR amplification Neuron 
Classical EGFR amplification, Loss of PTEN, chr7 
amplification, chr10 deletion 
Astrocytes 
Mesenchymal NF1 mutation, mutated TP53 and PTEN, chr7 
amplification, chr10 deletion 
Cultured astroglia 
Table 1 Verhaak Classification of GBM with genetic alterations and cell-type signature.  
 GBM was classified based on the molecular signature as proneural, neural, classical, 
or mesenchymal.  
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Specific genetic alterations define these different gliomagenesis pathways. Primary GBM 
is associated with Telomerase Reverse Transcriptase (TERT) promoter mutations (72%), 
Epidermal Growth Factor Receptor (EGFR) amplification (35%), Tumor Protein 53 (TP53) 
mutations (27%) and Phosphatase and Tensin Homolog (PTEN) mutations (24%) (Figure 1.1) 
26,34,35. On the other hand, secondary GBM is defined by mutations in IDH1, an increased 
incidence of TP53 mutations (81%), along with other tumor supressor pathway mutations 
21,34,36,37. Notably, the primary genetic alteration that differentiates primary GBM from lower 
grade gliomas and secondary GBM is IDH1 mutations 8. These mutations are the earliest 
detectable genetic alteration in low-grade diffuse gliomas and are found in over 80% of 
secondary GBM (Figure 1.1) but are virtually absent in primary GBM, found in less than 5% 8,26. 
Interestingly, primary GBMs that have mutated IDH1 behave more like secondary GBMs 32,38. 
The WHO now recognizes that mutations in IDH are a critical biomarker for glioma 
classification, which will be elaborated upon later (Figure 1.6). 
Figure 1.1 Genetic pathways to primary and secondary glioblastomas. 
  Adapted from Ohgaki and Kleihues 8. Glial progenitor cells develop de novo into 
primary GBM or acquire IDH mutations and become low grade glioma. There are specific 




Primary GBM Secondary GBM


























from (Ohgaki and Kleihues, 2013) (Lai et al., 2011) (Huse et al., 2011).
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Low-grade gliomas develop commonly with IDH1 mutations: 88% in astrocytomas and 
79% in oligodendrogliomas. PTEN mutations are rare and TP53 mutations are more frequent in 
astrocytomas than in oligodendrogliomas. Transcriptional regulator Alpha Thalassemia/Mental 
Retardation Syndrome X-linked protein (ATRX) is frequently mutated along with TP53 in 
astrocytomas (Figure 1.1). While the tumor suppressor Capicua (CIC) and Far-Upstream 
Element Binding Protein 1 (FUBP1) mutations and specifically 1p19q co-deletions are required 
in oligodendrogliomas but absent in diffuse astrocytomas (Figure 1.1) 8,39.  In both astrocytomas 
and oligodendrogliomas, mutations in IDH1 are thought to be the earliest event in gliomagenesis 
and cells then acquire specific mutations that drive lesions toward astrocytoma or 
oligodendroglioma. These tumors are classified as proneural and resemble OPCs.  
1.3 Oligodendrocyte progenitor cells as the cell of origin for proneural glioma  
 Oligodendrocyte progenitor cells (OPCs) are the most abundant proliferative cell in the 
adult CNS and are widely distributed throughout the brain 40-42 . OPCs express the proteoglycan 
Neural/Glial Antigen 2 (NG2), Oligodendrocyte Transcription Factor 2 (Olig2), and PDGFRa, 
and can be selectively labeled with antibodies against these markers (Figure 1.2). OPCs 
differentiate into oligodendrocytes (OLs) which generate myelin sheathes that insulate axons for 
faster action potential propagation. OPCs arise from the ventricular germinal zones of the 
embryonic neural tube and then proliferate and migrate away into developing gray and white 
matter where they remain in an immature and proliferative state, with the potential of 
differentiating into OLs. Unlike other progenitor cells, OPCs remain abundant in the adult brain 
40. OPCs are still able to generate new OLs in the adult CNS for myelin regeneration which 
changes through normal aging and disease as well as life events 43. NG2 and PDGFRa are 
downregulated as OPCs differentiate into OLs. Mature OLs have reduced proliferation 
 6 
(considered post-mitotic) and increased lipid biogenesis for myelin protein production 44-48. 
Epigenetic modulation is necessary for OPC differentiation 49.  Specifically, the active mark 
Histone H3 Lysine (H3K27) acetylation is found at OPC specific genes (i.e. Sox10 and Olig2) 50 
and deacetylation is necessary for OPC differentiation 51. The repressive histone mark H3K27 
trimethylation (H3K27me3) silences genes for OPC differentiation to myelinating cells 52.  These 





 While a great deal of attention has been focused on the possibility that gliomas arise from 
the transformation of neural stem cells (NSC), several lines of evidence support the idea that 
OPCs can also give rise to gliomas (Figure 1.3). The discussion below provides an overview of 
these two possibilities  In the adult brain, the ventricular-subventricular zone (V-SVZ) of the 
lateral ventricle and the subgranular zone (SGZ) of hippocampal dentate gyrus form the largest 
germinative areas 53. Neural stem cells (NSCs) self-renew and are responsible for neuron and 
glial cell production in these regions. NSCs give rise to glial progenitor cells which are mostly 
composed of OPCs. OPCs migrate towards the corpus callosum and the white matter tracts of 
fimbria fornix and striatum, and regulate their distribution and density through contact inhibition 
54,55. OPCs reside throughout the brain parenchyma, retain the capacity to proliferate and self-
renew, and are more abundant than NSC in adult brains 40,54,56,57. Gliomas are localized diffusely 
throughout different brain regions, unlike NSCs which are confined to the SVZ 58 (Figure 1.3).   
 Figure 1.2 Histology of 
murine oligodendroglioma 
grade II using H&E, Olig2, 
NG2 and PDGFRa.   




 Proneural gliomas express OPC lineage markers and their molecular signatures match 
each other 6,59. OPCs comprise about 0.1 to 1% (some studies suggest up to 5%) of the adult 
CNS and they are distributed practically uniformly throughout the brain and spinal cord in both 
gray and white matter 40. Due to the widespread nature of OPCs in the adult brain and their 
ability to actively proliferate, they are a good candidate as the cell of origin for gliomas 60,6170.  
 Growth factors have been strongly implicated in gliomagenesis. OPC migration and 
differentiation is regulated by PDGF ligand expression and stimulation of PDGFRa 44,62-65. Our 
group, as well as others, have shown that retrovirally injected PDGF overexpression causes 
glioma-like lesions 5,66-68. These gliomas retain OPC lineage markers (Olig2, NG2, PDGFRa) 
4,66,69. Our group has also found that isolated OPCs retrovirally infected with PDGF in vitro will 
form tumors when injected into mice (unpublished data). Together this data shows that OPCs are 





• Low in abundance
• Confined to a niche in SVZ
Glial Progenitor Cells
• PDGFR+/NG2+/olig2+ oligodendrocyte lineage
• Phenotypic plasticity (can revert)
• Capacity for self-renewal
• Abundant
• Widely distributed with migratory potential
Figure 1.3 Localization and distribution of neural stem cells in the SVC and glial 
progenitors throughout the adult human forebrain subcortical white matter.  
 Neural stem cells are shown in red and glial progenitors are shown in green. 
Distribution in gray matter not shown. Defining features are listed for neural stem cells and 





 Gliomagenesis can be produced by alterations in growth factor signaling (i.e., PDGF) and 
abnormalities in tumor suppressors (P53). PDGFRa amplification and TP53 mutations are 
commonly found in low-grade gliomas and secondary GBM and associated with the proneural 
molecular subtype (Figure 1.1) 21.  Our laboratory has created a murine model of gliomagenesis 
by deleting P53 and overexpressing PDGF, showing that these two alterations as sufficient to 
induce diffusely infiltrating gliomas that closely resemble human gliomas with the proneural 
phenotype (Figure 1.4). Furthermore, these mouse tumors and human proneural tumors are 
enriched for OPC markers and gene signatures (Figure 1.4). As the largest population of cycling 
cells in the adult brain, OPCs provide a pool of transformable, immature progenitors 4,7,40,70. 
Based on the genetic abnormalities found in proneural glioma and the localization of gliomas, 
OPCs are the inferred cell of origin although the process by which OPCs transform into 
proneural glioma is not fully understood. 
Figure 1.4 Mouse tumors driven by 
PDGF resemble human proneural 
gliomas with OPC expression 
signature. 
  Adapted from Lei, et al. 5. A). 
Heat map of the Pearson correlation 
analysis comparing the molecular 
profiles of mouse gliomas and the 
TCGA human GBM classifier 
sample set for glioma subtypes: 
proneural (PN), neural (N), classical 
(CL), and mesenchymal (MES). 
Each sample was assigned a class 
with the highest correlation 
coefficient. B). Mouse tumors and 
proneural human patients have the 
OPC signature based on GSEA. Red 
to blue color scale shows the range 
from highest correlation/ 
enrichment to lowest.  
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1.4 Isocitrate dehydrogenase function and cancer 
 IDH1 mutations are thought to be the earliest genetic alteration in proneural gliomas 
(Figure 1.1). In a sample of 220 gliomas from WHO grade II to IV, IDH1R32H mutated gliomas 
were located in the frontal lobe with a higher frequency than IDH-wildtype gliomas, which is 
consistent with other studies 3,23,71,72 (Figure 1.5). The frontal lobe has an abundance of white 
matter which is enriched with OPCs 7,73-75. The frontal white matter is the last brain region to 
complete myelination during development, giving the most time for OPCs to acquire the 
IDH1R132H mutation. As previously stated, low-grade glioma and secondary GBM that have a 
high incidence of IDH1R132H occur in younger patients which have more OPCs than adults. 
These clinical features, along with the remarkable similarity in expression profiles, further 
implicates OPCs as the cell of origin for IDH1 mutant glioma in the frontal lobe.  Furthermore, 
there is no evidence that IDH1 mutations arise spontaneously during tumor development in 
experimental glioma models 5,76-79. This further suggests that IDH1R132H is a mutation that 
occurs early in gliomagenesis. IDH1 mutations occur early in gliomagenesis at earliest diagnosis 
in virtually all glioma cells and is thus clonal.  Gliomas that form in the absence of IDH mutation 
acquire mutations in divergent pathways, while IDH-mutant gliomas show less molecular 
heterogeneity. IDH mutant oligodendrogliomas and astrocytomas both resemble OPCs, and later 
mutations led them down different transformation pathways (Figure 1.1). Through single cell 
sequencing others have found that IDH mutated tumors have shared glial lineage and 
developmental hierarchies suggesting a common progenitor 30. Together, these findings support 
the idea that the IDH1R132H mutation occurs early during gliomagenesis in OPCs and this 
restricts mutated cells to the OPC phenotype.   
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 As of 2016, the World Health Organization (WHO) incorporated molecular signatures 
into the histological classification of CNS tumors for better clinical classification (Figure 1.6) 1. 
This new classification grouped together astrocytic and oligodendroglial tumors as diffuse 
gliomas and uses specific genetic alteration to diagnose glioma. Tumors are now classified based 
on their IDH status because it is one of the most prognostic features of glioma and a biomarker 
for low grade gliomas and secondary GBM. Low-grade gliomas with mutant IDH are now 
classified as oligodendroglioma if they have 1p and 19q co-deletion and classified as 
astrocytoma if they have ATRX loss or TP53 mutations (Figure 1.6). This genetic distinction has 
allowed for most diffuse gliomas to be diagnosed as either oligodendroglial or astrocytic 1.  
Glioblastoma is also now classified according to IDH status, with IDH-wildtype being the more 
common form (about 90%) and clinically defined as primary GBM 8, and IDH-mutant, the less 
common (about 10%) and defined as secondary 8.  
Figure 1.5 Retrospective assessment 
of IDH1 mutant tumor distribution. 
 Adapted from  Xu, et al. 3. 220 
glioma samples were surgically 
resected and analyzed by PCR-
sequencing for mutation status. 
Frontal lobe is shown in blue, 
temporal lobe in gray, parietal lobe 
in green, occipital lobe in red, brain 
stem (thalamus) in yellow, spinal 
cord in pink and, cerebellum in 




















 Isocitrate dehydrogenase (IDH) mutations occur early in gliomagenesis (Figure 1.1), and 
likely affect the metabolic and epigenetic status of the cells harboring these mutations throughout 
tumor initiation and progression from progenitor cells to fully transformed glioma cells. IDH 
isoforms are enzymes that catalyze the oxidative decarboxylation of isocitrate to alpha-
ketoglutarate (a-KG), with oxalosuccinate formed as an intermediate. a-KG is a cofactor for 
multiple enzymatic reactions and is an antioxidant necessary for normal cell homeostasis 80. 
There are three human isoforms of this enzyme: IDH1, IDH2, and IDH3. IDH1 and IDH2 are 
nicotinamide adenine dinucleotide phosphate (NADP+) -dependent and share 70% sequence 
similarity with almost indistinguishable protein structures 81. IDH3 is nicotinamide adenine 
dinucleotide (NAD+) -dependent with a unique sequence and no tumor associated mutations 82. 
IDH2 and IDH3 are found in the mitochondrial matrix while IDH1 is mostly localized to the 









Diffuse astrocytoma, IDH mutant
Oligodendroglioma, IDH mutant and 1p/19q codeleted








Inconclusive or no 
genetic testing
*=not required for diagnosis
Low-grade glioma
Figure 1.6 Overview of 2016 WHO CNS tumor classification algorithm. 
  Adapted from WHO: World Health Organization 1,2 . The new classification separates 
the different categories for diagnosis based on histology, IDH status, and genetic parameters.   
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cytoplasm and peroxisomes 80. IDH1 is involved in glucose sensing and lipid metabolism while 
IDH2 is involved in oxidative respiration regulation 80. They use ADP and Ca2+ as positive 
effectors and ATP and NADPH as negative effectors 83. This system means IDH enzymes are 
inhibited when there is an abundance of energy and stimulated under low-energy conditions. 
Wildtype IDH1 and IDH2 are fundamental in the tricarboxylic acid (TCA) cycle regulation and 
are involved in energy metabolism in the cell 84. NADP+ is used by IDH1/2 as an electron 
acceptor to produce NADPH which helps maintain redox balance 82. Glutathione reductase uses 
NADPH to reduce glutathione disulfide (GSSG) to the glutathione (GSH) and thioredoxin 
reductases also use NADPH to reduce thioredoxin. Both processes are needed to resist oxidative 
stress. IDH1 is the main producer of NADPH in the human brain (accounting for as much as 
65%) 85.  IDH1/2 help protect the cell from oxidative stress by producing NADPH and a-KG, 
both of which have reductive properties and have been shown to protect against DNA damage 86. 
Thus, IDH mutations lead to increased ROS, which can result in oxidative damage to lipids and 
DNA 87-89. 
 Genetic screening has found that IDH is mutated in approximately 80% of low-grade 
glioma and secondary GBM 90. Specifically, a highly recurrent missense point mutation at the 
catalytic pocket of IDH1/2 was found 36,91. This somatic mutation is located at the position where 
isocitrate binds to the active site of the protein: at codon 132 for IDH1 or the analogous mutation 
at codon 172 for IDH2. IDH1 and IDH2 mutations are mutually exclusive but the IDH1 mutation 
is the most common 92.  IDH1 mutations at the same amino acid (R132) were discovered to be 
present in 12% of GBM, with more than 90% being arginine to histidine (IDH1R132H)  92,93. 
This mutation is found in 88% of astrocytomas, 79% of oligodendrogliomas, and 82% of 
secondary GBM 38,91,94. The IDH1R132H mutation is heterozygous, meaning there is still 
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unmutated IDH1 to perform some cellular processes 92. Interestingly, it is associated with longer 
survival in glioma patients 92. The fact that this mutation is common and occurs early in 
gliomagenesis, but patients with the mutation have prolonged survival, suggests its role is 
context specific with different functions in transformation and tumor progression.  
 There are challenges that currently hamper studying the role of IDH mutations in glioma. 
There are few pre-clinical models that express IDH1R132H; these models are hard to culture, 
and only a few mouse models form tumors. Because of these problems, some groups have 
hypothesized that IDH1R132H is actually a tumor suppressor 95. However, the idea that 
IDH1R132H acts as a tumor suppressor is not consistent with the clinically established findings 
described above. Thus, the tumorigenic effect of IDH1 remains a major unanswered question, 
but likely depends on the cellular context in which it occurs. We hypothesize that IDH1R132H 
first occurs in OPCs and therefore its tumor-initiating effects result from metabolic and 
epigenetic effects that facilitate OPC transformation (Chapter 4).  At later stages of tumor 
development, it is possible/likely that the metabolic alteration caused by IDH mutations act as a 
handicap that sensitizes the cells to oxidative stress, resulting in slower growth and increased 
sensitivity to radiation and chemotherapy 88. 
 IDH1R132H is a gain-of-function mutation which causes the IDH1 enzyme to switch 
from producing NADPH to consuming it, and thus causing changes in the redox balance (Figure 
1.7). IDH1 functions as an asymmetric homodimer with two quasi-open active sites that are 
accessible to isocitrate and the cofactor 80. When isocitrate binds to IDH1, the conformation 
changes to the quasi-closed position 96. When both the cofactor and isocitrate form a complex 
with the homodimer, a closed conformation results which then activates the enzyme 97,98.  When 
IDH1 is mutated and forms a mutant homodimer, it is unable to change into the closed 
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conformation and is thus enzymatically inactive 97. This altered enzymatic activity requires 
heterodimers composed of both mutant and wildtype IDH1.  Furthermore, when an IDH1R132H 
and a wildtype IDH1 enzyme form a heterodimer, there is reduced enzymatic activity toward a-
KG and an increased propensity for the quasi-closed conformation 96. The IDH1R132H mutation 
causes reduced isocitrate affinity by blocking the binding site 91. This mutation causes an 
increased in NADPH affinity by disrupting the configuration equilibrium 99. This shift in 
enzymatic affinity favors the reverse reaction of a-KG reduction to the (R)-enantiomer of 2-
hydroxyglutarate (2-HG) (Figure 1.7) 100. Although IDH1 does not have a direct function in the 
TCA cycle, when it is mutated it redirects carbon metabolites away from the TCA cycle and 












Figure 1.7 IDH1R132H causes 
an oncometabolic gain of 
function. 
 Adapted from Cairns, et 
al. 9. Isocitrate is converted to 
alpha-ketoglutarate (a-KG) by 
wildtype IDH1 with the 
production of reduced 
nicotinamide adenine 
dinucleotide phosphate 
(NADPH). When IDH1 is 
mutated at arginine 132 to 
histidine (IDH1R132H) it 
consumes NADPH and uses a-
KG as a substrate to make 2-
Hydroxyglutarate (2-HG).  
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  NADPH is a necessary metabolite for proliferation of both tumor and normal cells to 
increase fatty acid synthesis and reduce oxidative stress. IDH1R132H mutated tumors use 
NADPH to reduce a-KG to 2-HG and thus have reduced levels of NADPH 85,101. The loss of 
NADPH levels can lead to oxidative stress based on its role in regulating redox homeostasis. a-
KG is consumed by mutant IDH1 to make 2-HG. The cell uses glutaminolysis to replenish a-KG 
levels in mutated gliomas and could be a mechanism by which mutated IDH gliomas are able to 
increase their a-KG levels 102. Mutated IDH1 not only reduces the amount of the antioxidants 
NADPH and a-KG but also makes 2-HG.  
1.5 2-Hydroxyglutarate is an oncometabolite  
 2-HG is referred to as an “oncometabolite” that accumulates in IDH1-mutated gliomas to 
concentrations which can be over 50 times that of normal brain 100. The accumulation of 2-HG is 
associated with cellular transformation as well as metabolic and non-metabolic associated 
dysregulation 100,103-107. 2-HG inhibits ATP synthase activity and thus reduces ATP production 
by the mitochondrial electron transport chain which makes IDH1R132H cells more reliant on 
ATP production by glycolysis 108. There is no established physiological role of 2HG but D-/L-2-
hydroxyglutarate dehydrogenase (D/L-2HDH) degrades 2-HG back to a-KG, depending on the 
enantiomer. These enzymes are Flavin Adenine Dinucleotide (FAD)-dependent, independent of 
NAD+ or NADP+. D2HDH has high affinity but low capacity and has a slower enzymatic rate 
compared to IDH1R132H 109, causing a buildup of R-2HG. D-2-hydroxyglutaric aciduria is a 
rare neurometabolic disorder associated with increased R-2-HG caused by a defect in D2HDH. 
This is an inherited disease that is associated with brain abnormalities and with anaplastic 
oligodendroglioma 110. Similarly, defects in L2HDH cause increases of the S-enantiomer of 2-
HG (S-2-HG) and causes L-2-hydroxyglutaric aciduria. Interestingly, only patients with L-2-
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hydroxyglutaric aciduria have an increased risk for developing brain tumors 111. This further 
connects 2HG with tumorigenesis but by unknown mechanisms, however the prevalence of 
IDH1R132H mutations in glioma suggests it is a driver for gliomagenesis.  
 R-2HG and a-KG are identical with the exception of the oxygen atom at C2 in a-KG is 
replaced by a hydroxyl group. 2-HG acts as a competitive inhibitor to a-KG-dependent 
dioxygenases because of this structural similarity 105. These dioxygenases include Prolyl 
Hydroxylases (PHD), Ten-Eleven Translocation (TET) and the Jumonji C (JmjC)-domain 
containing subfamily of Histone Lysine Demethylases (KDM). PHD enzymes inhibit the 
transcription factor Hypoxia-Inducible Factor 1a (HIF-1a); mutated IDH1 gliomas as well as 2-
HG treated cells have been shown to have elevated HIF-1a and its target genes, such as Glucose 
Transporter 1 (GLUT1), Vascular Endothelial Growth Factor (VEGF), and Phosphoglycerate 
Kinase (PDK1) 96. The HIF-1a pathway stimulates tumor growth by transcriptionally regulating 
hypoxia responsive genes involved in proliferation, angiogenesis, apoptosis resistance, invasion, 
and migration 112-114.  It has been proposed that this allows IDH1 mutant glioma cells to escape 
from a hypoxic environment and promote tumor microenvironment formation 115. Thus, 
inhibiting PHD enzymes is one potential mechanism by which the IDH1R132H mutation may 














 TET and KDM enzymes function in many pathological and physiological processes 
including hypoxic stress, angiogenesis and cell differentiation 115. IDH1R132H produces 2-HG 
which inhibits the catalytic activity of a-KG-dependent dioxygenase and damages fundamental 
processes in DNA demethylation and histone modification. TET inhibition is thought to cause 
glioma Cytosine-Phosphate-Guanin (CpG) island hypermethylator (G-CIMP) phenotype 116. 
TET enzymes sequentially demethylate 5-ethylcytosine (5mC) to 5-hydroxymethylcytosine 
(5hmC), then 5-formylcytosine (5fC), and finally 5-carboxylcytosine (5caC) 117,118. TET 
enzymes maintain gene promoters in an unmethylated state so that they can be activated 119. G-
CIMP is defined as increased methylation of CpG islands which are preferentially located at the 
Figure 1.8 Mutated IDH1 promotes tumorigenesis through 2HG production. 
 a-KG and NADPH are antioxidants but they are consumed for 2HG production by 
IDH1R132H. D2HDH converts 2HG back to a-KG at a slower rate than ID1R132H makes 
2HG. 2HG inhibits a-KG-dependent dioxygenases: PHD, TET, and JmjC containing histone 
demethylases. PHD inhibition leads to the HIF-1a transcriptional network activation which 
promotes tumorigenesis. The cell becomes epigenetically deregulated with increased DNA 
methylation (G-CIMP) and histone methylation.  
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5’ end of genes that overlap with promoters 120. Hypermethylation of specific promoter 
associated CpG islands affects gene expression and is thought to contribute to tumorigenesis and 
has important prognostic implications (Figure 1.8). Expression of IDH1R132H has been shown 
to drive the G-CIMP phenotype and impede normal cellular differentiation in adipocytes and 
astrocytes 121 122. It is important to note that G-CIMP tumors have a significantly better survival 
outcome and feature the Proneural subtype signature 25. The G-CIMP phenotype is stable 
throughout tumor progression and recurrence 25. DNA methyltransferase (DNMT) maintains the 
DNA methylation pattern across cell divisions 123 and thus keeps IDH1R132H mutated cells 
hypermethylated. Decitabine depletes and degrades DNMT1 and treating IDH1 mutated gliomas 
with this drug allowed for the re-expression of genes associated with differentiation 124. This 
suggests that the IDH1 mutation is an early driver of tumorigenesis by 2-HG production that 
causes a distinct pattern of increased DNA methylation and epigenetic dysregulation which 
prevents differentiation. The genomic changes induced by IDH1R132H could lead to specific 
prognosis and help to determine effective treatment pathways, as seen with the MGMT promoter 
methylation as a determinant to Temozolomide therapy 125.  
1.6 Dysregulation of Histone Epigenetics in IDH1R132H 
 DNA strands are packaged into chromatin by wrapping around the nucleosome, which is 
comprised of the histone octamer: two copies each of H2A, H2B, H3, and H4. Posttranslational 
modifications (PTMs) of histones change the interaction between DNA and histones so that 
DNA strands can be more or less accessible to replication and transcription enzymes. Histone 
methylation is important for gene expression regulation and genetic stability. The ε-nitrogen on 
lysine residues can be mono-, di-, or tri- methylated and it can be associated with transcriptional 
activation or repression, depending on the location and amount of methylation 126.  Methylation 
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at H3K4 is associated with enhanced gene expression however methylation at H3K9, H3K27, 
and H4K20 is associated with repression 127. Methyl groups are removed from lysine residues by 
histone demethylases that fall into two families, JmjC domain-containing demethylases or amino 
oxidase homolog lysine demethylase 1 (KDM1) family 128. The JmjC demethylases are a-KG 
dependent and use iron and oxygen for hydroxylation to remove methyl groups. These 
demethylases are 200-fold more sensitive to 2-HG than PHD enzymes (discussed above) 
suggesting that mutant IDH1 has more of an influence in chromatin remodeling and could lead to 
profound differences between the epigenetics of wildtype and IDH mutated tumors  129.   
 IDH1R132H has been shown to increase various marks but most prominently the 
repressive marks trimethylation of histone H3 lysine 27 (H3K27me3) and di/trimethylation of 
histone H3 lysine 9 (H3K9me2/3) 122. Further, the increase of these repressive marks prevents 
cell differentiation in adipocytes and astrocytes 122. We will look at the effects of H3K27me3 in 
OPC differentiation in Chapter 4. 2HG was found to cause hyper-methylation of H3K9 which 
inhibits differentiation in fibroblasts 130. H3K9me3 has been found to be increased in some IDH1 
wildtype gliomas 131, suggesting it has roles in tumorigenesis independent of IDH1 status but this 
could be cell type specific. The KDM4 subfamily of demethylases (KDMA-D) demethylate 
H3K9me2/me3 as well as H3K36me2/me3, and H1.4K26me2/me3. KDM4s are overexpressed 
in multiple cancers and this is thought to drive tumorigenesis by promoting proliferation, 
genomic instability, angiogenesis, and metastasis 132.  
 Ubiquitously Transcribed Tetratricopeptide Repeats on the X Chromosome 
(UTX)/KDM6A and the functional isoform Jumonji Domain Containing 3 (JMJD3)/KDM6B 
specifically demethylate H3K27. Based on the TCGA database, UTX/KDM6A has been 
identified as a tumor suppressor based on the association of its loss or mutations with different 
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cancers 133. Loss of UTX increases H3K27me3 and specific genes are down-regulated to 
promote proliferation, adhesion, clonogenicity, and tumorigenicity in myeloid, lung, and bladder 
transformation 133. Despite the similarity between the two demethylases, the role of 
JMJD3/KDM6B is poorly understood and has been shown to behave both as an oncogene or as a 
tumor suppressor in different cancers.  
 Enhancer of Zeste Homolog 2 (EZH2) is a histone lysine N-methyltransferase enzyme 
and the main writer for H3K27 di- and trimethylation using S-adenosyl-L-methionine (SAM) as 
the cofactor. Methylation by EZH2 facilitates heterochromatin formation and gene silencing. 
EZH2 has been implicated in multiple cellular processes such as apoptosis, cell progression, cell 
proliferation, cell differentiation, and cell transformation  134. EZH2 is the enzymatic core 
subunit of Polycomb Repressive Complex 2 (PRC2) which has an important role in early 
embryonic development, proliferation, and cellular differentiation 135. The PRC2 complex is 
composed of Embryonic Ectoderm Development (EED), Suppressor of Zeste 12 (SUZ12), and 
Retinoblastoma (Rb)-Associated Proteins 46/48 (RbAp46/RbAp48). EZH2 was amplified and/or 
overexpressed in multiple types of cancer, including GBM, which was associated with poor 
prognosis 136. Proneural gliomas, compared to mesenchymal and classical, have increased 
expression of EZH2; this was positively correlated with Olig2 137, Interestingly, mutations in 
EZH2 that increase its trimethylation activity are found in some lymphomas and are thought to 
be an early tumorigenic event 138. Together this data suggests increased H3K27me3 promotes 
tumorigenesis, and this is specific to the proneural subset of glioma. IDH1R132H mutant 
gliomas have increased levels of H3K27me3 121 and we hypothesize that EZH2 inhibition could 
reverse the epigenetic alterations found in IDH1 mutant gliomas.  
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1.7 Histone H3 K27 mutations and diffuse midline gliomas   
 Lysine 27 of Histone H3 variant H3.3 (and to a lesser extent H3.1) is mutated to 
methionine in up to 80% of pediatric diffuse intrinsic pontine glioma (DIPG) and midline high-
grade astroctytomas in children and younger adults 139,140. These tumors are newly defined as 
diffuse midline gliomas, H3 K27M-mutant and are categorized as grade IV 1. Alterations in 
H3K27 are cell-context specific and different alterations can have tumorigenic effects in 
different cells. IDH mutations are common in gliomas that arise in the frontal lobe of young 
adults while brainstem gliomas virtually never harbor mutations in IDH but frequently have 
mutated H3K27. H3K27M mutant tumors are mutually exclusive with IDH1 mutation and EGFR 
amplification and commonly co-occur with p53 overexpression and ATRX loss 141. In fact, 
H3.3K27M and mutant IDH1 are synthetic lethal and influence metabolism (glycolysis and TCA 
cycle) and epigenetics in opposing ways 142. Specifically, H3.3K27M decreases and IDH1R132H 
increases global H3K27me3 142. H3.3K27M is termed an “oncohistone”143 and thought to be a 
driver mutation for diffuse midline gliomas and is associated with shorter survival and poorer 
therapy response compared to wildtype 140. These clinical and genetic findings strongly suggest 
that tumor-promoting effects of these epigenetic alterations are highly dependent on cellular 
context.  
 H3K27M mutant tumors have an altered epigenetic landscape. The mutation is thought to 
be gain-of-function by sequestering the PRC2 complex based on the structure and thus prevent 
EZH2 activity 108. The H3K27M mutation occurs only in a single allele of the 30 copies of 
histone H3 genes, meaning it accounts for only 3.6% to 17.6% of total histone H3 144. This 
suggests that the mutation is inhibitory to the PRC2 complex based on the global H3K27me3 
reduction. It has also been shown that the H3K27M mutation prevents the spread of H3K27me3 
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from PRC2 binding sites to larger domain 145. Methionine is thought to block the PRC2 subunits 
SUZ12 and EZH2 from binding to chromatin, preventing H3K27 trimethylation and in 
consequence increase H3K27 acetylation (H3K27ac) 146. H3K27ac is a mark of active 
transcription. By blocking the PCR2 complex, H3K27ac is permitted, and active transcription is 
promoted. Although it has been found that these tumors have global loss of H3K27me3, some 
genes retain H3K27me3 147. H3.3K27M constitutes a small part of total H3 and is incorporated 
into chromatin at low levels with little effect on strong PRC2 targets which could have multiple 
binding sites 147. Many genes still retain the trimethylation mark and these genes are associated 
with various cancer pathways 148. Further, it has also been found that EZH2 activity is necessary 
for diffuse midline glioma tumor growth in mice 134.   
 Another form of glioma with global H3K27me3 reduction is found in a subset of 
childhood posterior fossa (PF) ependymomas: PF-group A (PFA) 149. These tumors have an 
overexpression of EZH inhibitory protein (EZHIP) or harbor mutations in the protein. EZHIP 
(CXORF67) functions as a K27M-like peptidyl inhibitor of PRC2 which causes a global 
reduction of H3K27me3 and focal retention of H3K27me3 at CpG islands similar to the 
H3K27M oncohistone 150. In both DIPGs and PFA ependymomas, the reduction of H3K27me3 is 
thought to be due to sequestering the PRC2 complex at CpG islands which blocks H3K27me3 
spreading 151. The WHO will include H3K27me3 as a diagnostic biomarker in the future based 
on the association of different tumor types and H3K27me3 levels. Together this data suggests 
that excessive EZH2 activity is tumorigenic but even when PRC2 activity is reduced, some genes 
retain their trimethylation and promote tumorigenesis. Thus, inhibiting EZH2 is a potential 
therapeutic strategy. 
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1.8 Targeting H3K27me3 for cancer treatment.   
 EZH2 silences tumor suppressors and these genes seem to remain silenced even during 
pathological hypomethylation (i.e., DIPG/PFA). EZH2 inhibitors have become a promising 
treatment avenue to prevent methylation of tumor suppressor genes. The EZH2 inhibitor 
Tazemetostat (EPZ-6438) is an orally available, small molecule, selective, reversible, S-adenosyl 
methionine (SAM) competitive inhibitor of EZH2. Tazemetostat (trade name Taverik) was 
recently (January of 2020) approved by the FDA for the treatment of metastatic or locally 
advanced epithelioid sarcoma and also designated an orphan drug 152,153. It is still in multiple 
clinical trials for other types of cancers, such as non-Hodgkin’s lymphoma, malignant 
mesothelioma, diffuse large B-cell lymphoma, Integrase Integrator 1 (INI-1) deficient tumors 
and EZH2 mutated tumors 154,155. Groups have looked at using this drug for brain tumor 
treatment as well. In H3K27M DIPGs, Tazemetostat reduced global H3K27me3 and abolished 
tumor cell growth by induction of the tumor suppressor p16INK4A 147. H3K27me3 silences the 
INK4A–ARF locus which causes a decrease in expression of the tumor suppressors p16INK4A and 
p14/p19Arf 156, that regulate cellular senescence 157. Tazemetostat blocked medulloblastoma cell 
growth in vitro and in vivo and prolonged survival in xenograft models 158. It is thought to 
epigenetically reactivate adhesion G-protein-coupled receptor B1 (BAI1/ ADGRB1) by switching 
from the repressive trimethylation mark to the activating acetylation mark 158.  BAI1 is a tumor 
suppressor that blocks Mdm2 and thus stabilizes p53. However, another group found that 
Tazemetostat had no cytotoxic effect on pediatric glioma cells 159. It is still in multiple clinical 
trials which include patients with glioma, but these findings have not been published to date. 
Tazemetostat increases expression of genes that increase tumor suppressor activity as a 
secondary effect or directly removes silencing marks on tumor suppressors, however these 
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proteins are commonly mutated in cancers and prevent the full effect of treatment. To combat 
this and increase drug efficacy, using Tazemetostat in combination with another drug could be 
extremely beneficial. The finding that Tazemetostat is not cytotoxic in some tumor types (i.e., 
glioma) suggests its effects are cell type specific but it could be used in combination with other 
epigenetic modifiers to treat tumors.   
 Panobinostat (LBH-589) is a non-selective histone deacetylase inhibitor (pan-HDACi). 
Panobinostat interferes with histone and non-histone proteins to induce cell-cycle arrest 160-162, 
death-associated protein kinase (DAPK)-dependent autophagy, and DAPK-independent 
apoptosis through genetic modulation 163. Panobinostat (trade name Farydak) was approved by 
the FDA for multiple myeloma treatment 164. It is currently in other clinical trials including 
treatment for DIPG 165. Panobinostat causes prolonged hyperacetylation of histones by inhibiting 
HDACs. There have been 18 HDAC enzymes identified that belong to four classes in humans 
166. Pan-HDACi work on class I, II, and IV due to a zinc (Zn2+) ion in their catalytic site 166. 
Aberrant HDAC activity has been shown to contribute to cancer development 167. Similar to 
EZH2 inhibition, HDAC inhibitors (HDACi) are thought to de-repress silenced genes for cancer 
treatment 168-170. Transcriptome analysis has shown that HDACi treatment up-regulates a large 
number of genes, however some appear to be repressed 171-173. This suggests that HDAC 
inhibition could be amplified by demethylation to further de-repress silenced genes.  Others have 
found that EZH2 interacts with HDAC and have hypothesized that a combination of epigenetic 
treatments could be synergistic 174,175. I hypothesize that co-treatment of Tazemetostat and 
Panobinostat would be synergistic by additional gene activation than either monotherapy alone.   
 We hypothesize that Tazemetostat and Panobinostat in combination would have a 
synergistic effect on glioma cells. Furthermore, we propose that this synergistic effect would be 
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most pronounced in IDH1R132H mutated gliomas, which have increased H3K27me3 by 
demethylase inhibition from 2-HG. Tazemetostat reduces the H3K27me3, and this allows for 
more acetylation since H3K27 cannot be both methylated and acetylated at the same point. 
Panobinostat inhibits HDACs to promote H3K27ac. Using both drugs should promote 
acetylation by both inhibiting methylation and deacetylation (Figure 1.9). This two-hit approach 
should be synergistically cytotoxic to IDH1R132H mutant gliomas by increasing transcription of 


















Figure 1.9 Targeting the crosstalk between trimethylation and acetylation at H3K27 with 
Tazemetostat and Panobinostat. 
 IDH1R132H produces 2-HG which inhibits the H3K27me3 demethylases 
UTX/KDM6A and JMJD3/KDM6B. Tazemetostat inhibits EZH2, the histone 
methyltransferase for H3K27. Histone acetyltransferase (HAT) acetylates H3K27 while 
HDAC deacetylates it. Tazemetostat reduces H3K27me3 and Panobinostat inhibits HDAC to 
increase H3K27ac. Using the co-treatment shifts the equilibrium towards even more 
increased acetylation than either monotherapy.   
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1.9 Summary.   
• Gliomas can be classified into four molecular subtypes: proneural, classical, 
mesenchymal, and neural 
• Expression profiles reveal the cell of origin for each subtype with proneural high-grade 
gliomas arising from OPCs 
• IDH1R132H mutant gliomas are frequent and associated with the proneural subtype with 
the OPC phenotype 
• IDH1R132H converts a-KG to the oncometabolite 2HG  
• 2HG is an a-KG competitive inhibitor which inhibits H3K27me3 demethylases causing 
an increase in the repressive mark H3K27me3 
• EZH2 inhibition decreases H3K27me3 allowing for increased H3K27ac giving a 






Chapter 2: Determine the metabolic, epigenetic and transcriptional 
effects of IDH1R132H and 2-Hydroxyglutarate on glioma cells 
 
 Glioma can be divided into subtypes based on gene expression profiling. These subtypes 
are associated with different sets of genetic alterations, inferring a functional relationship 
between genotype and phenotype 6,176 177. The majority of low grade gliomas and secondary 
glioblastomas have the proneural phenotype 6 and oligodendrocyte progenitor cells (OPC) are 
considered the cell of origin 59. As such, the gene expression profiles of OPCs and proneural 
cells resemble each other 6. The proneural glioma phenotype is characterized by specific genetic 
alterations: mutations in the epigenetic modifier Isocitrate Dehydrogenase 1 (IDH1), mutations 
or loss of the tumor suppressor p53, and amplification of the oncogenic Platelet-Derived Growth 
Factor Receptor alpha (PDGFRa) 6. The specific genetic alterations found in proneural gliomas 
suggests a connection between genotype and phenotype however the underlying mechanism is 
not fully understood.   
 Epigenetic processes modify the expression of genes and connect genotype to developing 
phenotype. These interactions influence gliomagenesis but are unexplored compared to genomic 
and transcriptomic analysis. Cellular transformation is connected to dysregulation of 
transcription associated with increased oncogene activity and repression of tumor suppressors. 
Epigenetic modifications are necessary for the changing gene expression in OPCs and for their 
differentiation 178. This differentiation is driven by post-translational modifications of specific 
amino acid residues on nucleosomal histone N-terminal tails for gene expression modulation 178.  
 Tri-methylation of the lysine residue K27 on histone H3 (H3K27me3) leads to 
transcriptional repression. Trimethylation of K27 has been associated with maintenance of ES 
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cell pluripotency 179.  Enhancer of Zeste 2 (EZH2) is the catalytic subunit of Polycomb 
Repressive Complex 2 (PRC2), the main writer for H3K27 di- and tri- methylation 180. It has 
been found that EZH2 is overexpressed in various solid tumor types 181,182, including GBM 183, 
and that blocking PRC2 in human cancer cell lines with high EZH2 expression inhibited growth 
184,185, suggesting unchecked PRC2 activity causes H3K27 hypermethylation and tumor 
suppressor inhibition 186. However, disruption of EZH2 expression was sufficient to cause T-
acute lymphoblastic leukemia (T-ALL) in mice 187. EZH2 appears to have both tumor suppressor 
and oncogenic functions 186, suggesting a role in regulating phenotype, possibly in a cell-type 
specific manner. The EZH2 inhibitor Tazemetostat was recently approved by the FDA for 
advanced or metastatic epithelioid sarcoma and categorized as an orphan drug 152. Tazemetostat 
is still in clinical trials for other cancers and the influence of EZH2 in glioma suggests that EZH2 
inhibitors could be a useful tool to explore the phenotypic effects and therapeutic potential of 
targeting specific epigenetic alterations in glioma. 
 Many enzymes that modify chromatin require cell metabolism intermediates (such as α-
KG) for enzymatic activity showing a direct connection between cell metabolism and epigenetics 
188. The histone demethylases, UTX/KMD6A and JMJD3/KDM6B, demethylate di/tri-
methylated H3K27. Both demethylases contain a Jumonji (JmjC) catalytic domain which uses α-
ketoglutarate (α-KG) as a cofactor to oxidize and remove the methyl group 189. IDH1 produces α-
KG within the TCA cycle during glucose metabolism, however mutant IDH1 (IDH1R132H) 
produces 2-hydroxyglutarate (2-HG), an α-KG competitive inhibitor, decreasing H3K27 
demethylation. Furthermore, it has been found that IDH1 mutations increase H3K27me3 121. 
Interestingly, H3K27 mutations are seen in a select subset of midline mutations, usually found in 
children (Diffuse Intrinsic Pontine Glioma, DIPG), however IDH1 mutations are mutually 
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exclusive with these mutations 190. Patients with mutations that alter H3K27me have poor 
clinical outcomes with no meaningful treatment 191. We therefore hypothesize that targeting 
H3K27 would have meaningful therapeutic advantages. We used the EZH2 inhibitor 
Tazemetostat to better understand the biological processes that epigenetically regulate glioma 
cells.  
2.1 Results 
2.1.1 IDH1R132H mutated tumors have same survival as wild-type and appear as high-grade 
proneural gliomas.  
 
 The IDH1R132H mutation was found in over 70% of grade II-III gliomas and secondary 
GBM91 suggesting that it is a driving mutation in tumor development. To determine the influence 
of this mutation on gliomagenesis Dr. Frank Garcia developed a mouse model of IDH1 mutated 
glioma. Mice with floxed p53 were stereotactically injected to target the glial progenitors of the 
subcortical white matter with retrovirus expressing PDGFB and cre to drive tumorigenesis alone 
as a control or along with IDH1R132H (Figure 2.1A). This model allows us to compare 
tumorigenesis and phenotype between wild-type and IDH1R132H tumors while controlling for 
other genetic alterations. Tumors were monitored by luciferase reporter, but no difference was 
seen in the growth kinetics. Both IDH1 mutant and wild-type murine gliomas reached end-stage 
by tumor morbidity with a median survival of 40 days post-injection (Figure 2.1B). Delivering 
IDH1R132H along with PDGFB and deleting p53 did not have a survival outcome, suggesting 
the IDH mutation did not facilitate tumorigenesis in this co-delivery model, possibly because p53 
deletion and PDGFB overexpression drive the tumor too strongly to be influenced by another 
mutation. Tumors collected at morbidity showed large diffusely infiltrating lesions expanding 
from the site of injection by hematoxylin and eosin staining (Figure 2.1C).  The histology shows 




2.1.2 IDH1R132H mutation increases 2-Hydroxyglutarate. 
 
 IDH1 normally converts isocitrate to α-KG, however the R132H mutation changes the 
enzymatic properties to cause a higher affinity for α-KG rather than isocitrate and produces 2HG 
100,192. 2HG is created under physiological conditions, however IDH1R132H produces elevated 
levels which have metabolic and epigenetic influences 193. We used matrix-assisted laser 
desorption ionization imaging mass spectroscopy (MALDI-IMS) to determine if IDH1R132H 
expressing tumors have increased 2HG compared to normal brain and wild-type IDH1 tumor 
tissue. IDH1R132H mutant gliomas had increased 2HG specifically in the tumor region (Figure 
2.2A/B). We also looked at α-KG but found no difference in mutant tumors compared to wild-










Figure 2.1 IDH1R132H mutant tumor model does not influence murine survival with 
indistinguishable histology.  
A) Schematic of retroviral delivery conditions used to create gliomas with wildtype 
(WT) or mutant IDH1 (R132H) steotactically injected into transgenic mice with floxed p53 
and stop-floxed fusion mCherry/Luciferase reporter (LSL-mCh/Luc). B) Kaplan-Meier curve 
comparing the survival of WT and R132H mouse groups, Log-rank (Mantel-Cox) test p-value 
= 0.16 and Gehan-Breslow Wilcoxon test p-value = 0.46. C) WT and R132H tumors are 
histologically indistinguishable. Upper panel (1.5x) with 1mm scale bar and lower panel 




 To further analyze the metabolic profiles of IDH1R132H gliomas, we isolated cells from 
our wild-type and mutant glioma models. After performing metabolomic analysis on these cells, 
we found that 68 metabolites were significantly altered, and these included increased 2HG and α-
KG in mutant glioma cells (Figure 2.3A/B). Interestingly, the mutated glioma cells also had 
increased NADPH and glutathione. This was contrary to previous studies which found a 
reduction in NADPH in IDH1R132H tumors 85. To better understand these differences, we will 
verify the finding in more samples and measure NADPH in IDH1R132H knock-in model, in 
which IDH1R132H is not overexpressed. Unmutated IDH1 reduces NADP+ to NADPH as 
cofactors in the conversion of isocitrate to α-KG, and NADPH is necessary for glutathione 
reduction. One possible explanation for the increased NADPH and glutathione seen in our model 
A. B.
H&E 
Normal R132H WT 




x10 Normal R132H WT 
Overlay (Glutamate + 2-HG) 
Normal R132H WT 
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Normal R132H WT 
Figure 2.2 MALDI-IMS comparing 2HG of normal, WT, and R132H murine brains. 
A) Top left panel of H&E staining to show tumor margins. Panels demonstrate two-
dimensional ion density images for α -ketoglutarate (top right panel) and 2-hydroxyglutaric 
acid (bottom panel) collected at a spatial resolution of 200µm. B) Quantification of average 
concentration (nmol/mg) of 2-HG across tumor (TT) and non-tumor (NT) regions One-way 
ANOVA with Tukey’s correction for multiple comparison was used. **** p-value <0.0001. 
Work done by Dr. Frank Garcia and in collaboration with Dr. Richard Caprioli.  
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of IDH1R132H, could be that the unmutated isoform of IDH1 becomes more active, increasing 
NADPH and α-KG probably as a regulatory mechanism to reduce the influence of 2HG. This 
could have to do with cellular culture conditions, which have excess nutrients that would not be 
available in the tumor microenvironment.  
 
 
 Based on pathway analysis using MetaboAnalyst 4.0 10 IDH1R132H glioma cells had 5 
different pathways significantly affected, with FDR<0.05, and 3 pathways trending toward 
significance (Figure 2.3C). The TCA cycle was one of these pathways as previously reported 194 
with fumarate, citrate, cis-aconitate, succinate and α-KG being altered. Many of the other altered 





Status p -log(p) Holm p FDR Impact
Alanine, aspartate and 
glutamate metabolism 8/28 7.49E-06 11.802 6.29E-04 3.38E-04 0.32212
Arginine biosynthesis 6/14 8.05E-06 11.73 6.68E-04 3.38E-04 0.36548
Glycine, serine and 
threonine metabolism 8/34 3.61E-05 10.229 0.00296 0.001011 0.47584
Citrate cycle (TCA cycle) 5/20 8.97E-04 7.0168 0.072634 0.018831 0.26151
Aminoacyl-tRNA 
biosynthesis 7/48 0.002512 5.9867 0.20095 0.0422 0
Arginine and proline 
metabolism 5/38 0.016543 4.1018 1 0.2316 0.26975
Pantothenate and CoA 
biosynthesis 3/19 0.03858 3.255 1 0.43431 0.18214
Cysteine and methionine 










































Figure 2.3 Metabolomic analysis comparing WT and IDH1R132H glioma cells.  
A) Heatmap of significantly different metabolite analysis comparing wild-type and 
IDH1R132H glioma cells. Color scale intensities represent z-score for higher expression (dark 
blue) and lower expression (light blue). B) Bar graph showing peak metabolite expression of 
a-ketoglutarate and 2-hydroxyglutarate with student’s T-test statistical analysis. C) Pathway 
analysis of significantly different metabolites using MetaboAnalyst 4.0 10. Match status shows 
the number of metabolites altered out of the total metabolites for that pathway.  
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metabolism pathway which both require α-KG as a substrate. α-KG is decarboxylated by α-KG 
dehydrogenase to succinyl-CoA and CO2 in the TCA cycle. α-KG can be produced 
independently of the TCA cycle from glutamate by oxidative deamination. Based on the pathway 
analysis, IDH1R132H appears to have increased 2HG levels, and associated alterations in α-KG 
pathways. It also suggests that the cells have some type of regulatory mechanisms in culture to 
try and shift the enzymatic process to increase α-KG. To better understand this, we will measure   
α-KG levels in our knock-in model to see if heterozygous IDH1R132H expression has a different 
effect on metabolites.  
2.1.3 ID1R132H mutation restricts normal differentiation.  
 
 We performed RNA sequencing on the IDH1R132H mutant and wildtype mouse gliomas 
to see if these tumors recapitulate the molecular profile of human proneural gliomas. First we 
compared the expression profile of the wildtype (n=5) and IDH1R132H (n=6) murine tumors to 
the TCGA database using Gene Set Enrichment Analysis (GSEA), with focused analysis on the 
Verhaak subtype classifier genes: Proneural (PN), Classical (CL), Mesenchymal (MES), Neural-
high (NA) and Neural-low (NL) 21,195.  We found that both the IDH1R132H mutant tumors and 
the wildtype tumors were highly enriched in the PN molecular subtype and depleted in the CL 




 We then performed differential gene expression on the IDH1R132H mutant and wildtype 
tumors to see what genetic changes the mutation causes. We further analyzed the Differentially 
Expressed tumor set by performing GSEA using the Barres murine brain transcriptome 









































Figure 2.4 RNA sequencing of wildtype and IDH1R132H murine tumors are proneural 
and mutant gliomas are less lineage-restricted.  
A) Heatmap of gene set enrichment analysis (GSEA) to compare the RNA sequence 
profiles of IDH1R132H mutant and WT murine gliomas to the four glioma molecular 
subtypes 6 but with splitting Neural into higher or lower expression within the subtype: 
Proneural (PN), Neural-high (NL), Neural-low (NA), Classical (CL), and Mesenchymal 
(MES). Samples are grouped as mouse and TCGA human samples. Color scale for high-
enrichment (red) and low-enrichment (green) z-score. Work done by Dr. Franklin Garcia. 
B/C) GSEA of significant differentially expressed genes using cell specific brain 
transcriptome gene sets11. Gene sets were made with the top 200 enriched genes based on 
fold change above average for each cell type: astrocytes, oligodendrocytes, neurons, OPCs, 
newly formed oligodendrocytes, myelinating oligodendrocytes, microglia, and endothelia. 
Only showing OPC lineage (B) and significant GSEA (neuron, astrocytes, myelinating 
oligodendrocytes, and microglia) (C).   
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database11 to create cell type specific gene sets with the top 200 enriched genes for each cell 
type, based on fold change above average expression. This allowed us to create gene sets for 
astrocytes, oligodendrocytes, neurons, OPCs, newly formed oligodendrocytes, myelinating 
oligodendrocytes, microglia, and endothelia for the analysis. Based on this analysis, the 
IDH1R132H tumors expressed more OPC genes but this was not significant (Figure 2.4B). The 
wildtype tumors significantly expressed more neuron, astrocyte, myelinating oligodendrocyte, 
and microglia genes (Figure 2.4C). This suggests that the IDH1R132H tumors are more lineage-
restricted to the OPC phenotype.  It is also possible that the IDH-wildtype tumors could be more 
heterogenous in composition, as has been proposed in human gliomas 196,197, but this possibility 
needs to be explored through further analysis of the mouse model. 
2.1.4 2-Hydrogyglutarate and IDH1R132H increase H3K27me3 and inhibiting H3K27me3 
causes less lineage restriction. 
 
 Based on the increased 2HG levels in the IDH1R132H mutant tumors as well as the 
transcriptomic data, we wanted to see if there were epigenetic changes. 2HG is a competitive 
inhibitor of α-KG dependent dioxygenases, such as the Histone H3K27me3 demethylases, 
UTX/KMD6A and JMJD3/KDM6B 105, causing the hypermethylator phenotype 121. It has been 
found that various tumor models have different EZH2 inhibitor sensitivities198 so we first wanted 
to see if our tumor model was sensitive. We found that our wildtype and IDH1R132H high-grade 
glioma models were equally insensitive to Tazemetostat and did not reach IC50 even at 64µM 
(Figure 2.5) although treatment was able to cause near complete loss of H3K27me3 at 5µM 




 I hypothesize that IDH1R132H and 2HG treated glioma cell will have increased 
H3K27me3 and I further hypothesize that Tazemetostat will block H3K27me3. We used a 
membrane-permeable precursor form of 2-HG, octyl(R)-2-hydroxyglutarate. Cells were plated 
and pre-treated with Tazemetostat or DMSO; 16 hours later they were treated with 2HG or 
DMSO and retreated with Tazemetostat or DMSO for 24 hours, giving 4 conditions: control, 
Tazemetostat, 2HG, or 2HG and Tazemetostat (Figure 2.6A). We included the pretreatment with 
Tazemetostat, because Tazemetostat is more effective over time (see data in Chapter 2), whereas 
2HG has a much briefer course of activity. Cells were harvested and histones were acid 
extracted. 2HG and IDH1R132H significantly increased H3K27me3 compared to control 
wildtype cells (Figure 2.6B).  Also, EZH2 inhibition reduced H3K27me3 significantly in every 
condition. Notably, Tazemetostat increased H3K27ac compared to control (Figure 2.6B), 
revealing that Tazemetostat is having reciprocal effects on methylation and acetylation at 
H3K27. The increase in acetylation suggests there is a crosstalk between H3K27me3 and 
H3K27ac. While the mechanisms of this crosstalk have not yet been deciphered, it is known that 
a single point on a histone cannot be both methylated and acetylated, suggesting that increasing 
Figure 2.5 Tazemetostat 
dose vs. response in 
wildtype and IDH1R132H 
glioma cells. 
 Dose vs. response of 
wildtype and IDH1R132H 
glioma cells with increasing 
doses of Tazemetostat 
(Log2 scale). Viability 
determined by Cell Titer 
Glo assay normalized to 
untreated control. Line 
represents nonlinear fit.  
















methylation would decrease acetylation. However, the crosstalk between H3k27ac and 
H3K27me3 is likely to be more complicated. We will go into this further in chapter 3.   
 
  
 Based on this data, I hypothesize that EZH2 inhibition will increase H3K27ac more over 
a longer period of time.  When glioma cells were treated with Tazemetostat for 112 hours, 
H3K27me3 was almost completely absent and H3K27ac was significantly increased in both the 
wildtype and IDH1R132H cells (Figure 2.7). This suggests that EZH2 inhibition has lasting 
effects on glioma cell’s epigenetic status. We found that glioma cells could survive and 
proliferate in the presence of Tazemetostat treatment for several weeks. These findings raise the 
possibility of using Tazemetostat to test the effects of prolonged epigenetic reprogramming on 
glioma cell phenotype and sensitivity to combination therapies. 
H3
H3K27me3
- +     
WT





Figure 2.6 2HG and IDH1R132H increase H3K27me3 while EZH2i increases H3K27ac.  
A) Western blot of acid extracted histones from wildtype, octyl-R-2HG (100uM) 
treated or IDH1R132H cells after 24 hours with or without Tazemetostat (EZH2i) 5uM 16-
hour pretreatment. B) Quantification of H3K27me3 and H3K27ac normalized to total H3 
from three independent experiments. Represented as fold change compared to wildtype 
control value for each experiment. Statistical analysis done as one-way ANOVA with 





 We analyzed the cells by immunofluorescence to better understand the relationship 
between cellular phenotype and epigenetics. Cells were treated with the same time course using 
2HG and the EZH2 inhibitor Tazemetostat (Figure 2.6) and then fixed. We stained the cells for 
DAPI to determine individual cells, H3K27me3, and Ki67 which is a proliferation mark (Figure 
2.8). We quantified the immunofluorescence by making a mask of DAPI positive cells and using 
ImageJ to find the average cells staining intensity for H3K27me3 and Ki67. This allowed us to 
find individual cells and then assess each cell’s average staining intensity. It is important to note 
for H3K27me3, we did not normalize to total H3 as previously done for the western blots so the 
cell specific changes could be due to total amounts of histone levels, not just H3K27me3. EZH2 
inhibition significantly reduced the average H3K27me3 intensity per cell (Figure 2.8B). 2HG 
increased H3K27me3 however IDH1R132H did not. This is probably due to cellular differences 
and different amounts of total H3 in the different cell types. By treating the same cell type 
























Figure 2.7 Long-term EZH2i further reduces H3K27me3 and increases H3K27ac in WT 
and IDH1R132H glioma cells. 
A) Representative western blot of wildtype and IDH1R132H glioma cells after 116 
hours of Tazemetostat (5uM). Histones were acid extracted. B) Quantification of wildtype 
glioma cells H3K27me3 and H3K27ac normalized to total H3 from 3 independent 
experiments. Represented as fold change to control for each experiment. C) Quantification of 
IDH1R132H glioma cells H3K27me3 and H3K27ac normalized to total H3 from 3 
independent experiments. Represented as fold change to control for each experiment. 
Statistical analysis performed as a student’s T-Test.  
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same cell type would be equivalent. But the IDH1R132H cells were prepared from different 
tumors and could have completely different basal levels of total histone. We looked at the 
labeling index of H3K27me3 positive cells from three independent experiments (Figure 2.8B). 
Again, Tazemetostat significantly reduced the amount of H3K27me3 positive cells. 2HG 
increased the number of positive cells but the IDH1R132H cells were more variable.
 IDH1R132H is thought to be a driver mutation in early gliomagenesis. We used Ki67 to 
measure proliferation to see if 2HG or ID1R132H changes cellular proliferation. Ki67 is a 
biomarker of proliferation because it is absent in quiescent cells. Interestingly, 2HG reduced 
Ki67 staining, both by cellular intensity and labeling index and EZH2 inhibition blocked this 
reduction (Figure 2.8C). There was a slight, but significant, increase in Ki67 labeling index for 
the IDH1R132H cells with or without Tazemetostat. This suggests that short term 2HG treatment 
reduces proliferation in high grade glioma cells through H3K27me3. It is important to note that 
2HG could have a different effect on not fully transformed cells, such as OPCs.  Interestingly, 
IDH1R132H cells which acquired their mutation during tumor initiation have increased Ki67 
labeling index. This suggests that the IDH1R132H cells when grown in culture are actually more 
proliferative meaning, they must have overcome the 2HG-reduced proliferation or the occurrence 




2.1.5 Tazemetostat treatment allows for unrestricted lineage gene expression 
 
  Based on the phenotypic changes in the IDH1R132H tumor model compared to 
wildtype, I hypothesized that EZH2 inhibition would cause the tumor cells to express genes 
outside of the OPC phenotype. The IDH1R132H mutation causes an increase in H3K27me3 121 

















































































































































































































































































































































































































































Figure 2.8 Immunofluorescence of wildtype, 2HG, and IDH1R132H glioma cells treated 
with or without Tazemetostat. 
A) Representative immunofluorescence photos (20X) of wildtype, octyl-R-2HG 
(100uM) treated, and IDH1R132H glioma cells treated with 5µM Tazemetostat (EZH2i) or 
DMSO. Cells were fixed with 4% PFA then stained for Ki67 (Rat) and H3K27me3 (Rabbit). 488 
Rat secondary was used for Ki67 and 568 Rabbit secondary was used for H3K27me3. B) 
Quantification of H3K27me3 staining. First graph is from one experiment showing relative 
intensity per cell. Second graph shows the H3K27me3 labeling index with percent of positive 
cells from three independent experiments. C) Quantification of Ki67 staining. First graph is 
from one experiment showing relative intensity per cell. Second graph shows the Ki67 labeling 
index with percent of positive cells from three independent experiments.  
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restricted and thus more proneural. As a first experiment, we treated wildtype tumor cells with 
the EZH2 inhibitor Tazemetostat to see if less H3K27me3 would cause the cells to be even less 
lineage-restricted. We found that 64 genes were differentially expressed after 72 hours of 
Tazemetostat treatment (Figure 2.9A/B). All of the genes except one (Vim) were upregulated, as 
expected when removing a repressive mark. The most significantly upregulated gene was Ndn 
which encodes necdin (Figure 2.9B). In humans, NDN is located in the Prader-Willi syndrome 
(PWS) chromosome region. Loss of specific genes on chromosome 15 causes PWS in which 
patients present with obesity, intellectual impairment and behavioral problems 199. Necdin is 
expressed in post-mitotic neurons, is a growth suppressor that promotes cell cycle arrest, and is a 
putative tumor suppressor 200. It is downregulated in ovarian, colorectal, and other cancers and is 
thought to be downregulated by hypermethylation 201-203. We will use necdin as a validation of 
Tazemetostat treatment.  
 We performed GSEA on these genes using the Barres murine brain transcriptome 
database as previously described. We found that cells treated with the EZH2 inhibitor expressed 
more neuronal (such as Ndn) and endothelial-lineage genes (Figure 2.9E). There was no 
significant change in OPC genes, since Tazemetostat treatment removes the repressive mark 
causing an increase in gene expression; although the cells become less OPC-like, they cannot 
decrease their OPC lineage genes. This suggests that increased H3K27me3 induces OPC 
phenotype, i.e., IDH1R132H mutant tumors, and that reduced H3K27me3 decreases OPC 




 I hypothesize that treating wildtype or IDH1R132H mutant glioma cells with the EZH2 
inhibitor will increase necdin protein expression. We also treated cells with 2HG to see if there is 
















Figure 2.9 Tazemetostat treated metabolically stressed glioma cells are less lineage-
restricted.   
A) Heatmap of significant differentially expressed genes after 72 hours of 
Tazemetostat (EZH2i) treatment. Color scale intensities refer to normalized enrichment score 
(z-score) for high-enrichment (red) and low-enrichment (green). B) Volcano plot of 
differentially expressed genes shown as a comparison of -Log10 P-value to Log2 Fold change 
for each gene. Non-significant genes are shown in gray, significant Log2 Fold Change (FC) 
shown in green, significant P-value shown in blue and significant Fold Change and P-value 
shown in red. Ndn is labeled. C) Gene Set Enrichment Analysis (GSEA) using the Barres 
murine brain transcriptome database11 to create cell type specific gene sets with the top 200 
enriched genes for each cell type, based on fold change above average expression. Only the 
significant enriched gene sets are shown.  
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RNA sequencing data was collected from cells cultured for 72-hours, but to make sure there 
were changes in necdin protein expression we cultured cells for longer. Cells were plated then 
pretreated with Tazemetostat or DMSO for 16 hours. The cells were then treated with 2HG for 
72 hours in the presence of Tazemetostat or DMSO and then retreated and collected at 96 hours 
(Figure 2.10A). This time course was to make sure we could see changes in necdin expression, 
since we saw changes in RNA expression after 72 hours of Tazemetostat treatment to still allow 
for 2HG activity which we saw influencing H3K27me3 after only 24 hours. To look at necdin 
levels we developed a method to fractionate the cells and then acid extract the nuclear fraction 
for histone levels (Figure 2.10B). As expected from previous experiments, Tazemetostat reduced 
H3k27me3 to almost undetectable levels (Figure 2.10C). IDH1R132H and 2HG treated cells did 
not have increased H3K27me3 with this longer time course, suggesting cells have some type of 
negative regulatory system to reduce H3K27me3 or reach a plateau when cells are cultured for 
long periods of time. To further understand how culture conditions influence H3K27me3, we 
subjected cells to different types of stress, as in Appendix A. H3K27ac levels were significantly 
increased in the IDH1R132H cells (Figure 2.10D). A similar trend was seen in the wild type and 
2HG treated cells, however the effects did not reach significance in these conditions, due to 
variability in the levels of H3K27ac within treatment groups.  
 In each condition, Tazemetostat significantly increases necdin expression (Figure 2.10E). 
Interestingly we found that IDH1R132H glioma cells expressed less baseline levels of necdin. 
Necdin is a putative tumor suppressor and with reduced expression in IDH1R132H cells, 
suggesting this could be a mechanism by which IDH1R132H is tumorigenic. Necdin expression 
is controlled by H3k27me3 and IDH1R132H cells are hypermethylated. By treating cells with 
Tazemetostat and reducing H3K27me3, necdin is no longer repressed. The increase in necdin 
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expression is a validation of our RNA-sequencing data in which Tazemetostat treatment 




2.2 Discussion  
 We developed a model of IDH1R132H and wildtype proneural glioma in mice. The 
IDH1R132H mutation did not change survival outcome in this glioma model. However, we 
introduced the IDH1R132H mutation at the same time as deleting p53 and overexpressing 
PDGFB. In patients with low-grade proneural gliomas, IDH1R132H is the first detectable 
genetic alteration 8. This suggests the mutant IDH1 could have different effects in untransformed 
cells compared to cells which have tumorigenic lesions (p53 deletion and PDGF amplification).  
 The IDH1 mutation causes gain-of-function enzymatic changes which produce the 
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Figure 2.10 Tazemetostat increases Necdin protein levels.  
A) Timeline of experimental drug treatments. B) Representative western blot of 
wildtype, octyl-R-2HG (100uM), and IDH1R132H cells treated with or without 5µM 
Tazemetostat (EZH2i).  Cells were fractionated for the cytoplasmic fraction (CF) and the 
nuclear fraction (NF) was acid extracted for histones. C) Quantification of H3K27me3 
normalized to total H3 from three independent experiments. D) Quantification of H3K27ac 
normalized to total H3 from three independent experiments. E) Quantification of necdin 
normalized to total actin from three independent experiments. All graphs shown as fold 
change to wildtype control and ratio paired t-test was performed for statistical analysis.   
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produces 2HG at higher levels than wildtype tumors or normal brain and this is localized to the 
tumor regions. Importantly we saw no changes in a-KG levels in the IDH1R132H mouse model 
compared to either the wildtype tumors or normal brains. Cultured glioma cells from the 
IDH1R132H model had increased 2HG and a-KG. This suggests that the culture conditions 
change the metabolomics of the tumor cells. The culture conditions have many nutrients that 
tumors would be deprived of such as growth factors, glucose, and supplements. We can assume 
that there is increased a-KG in the cultured cells due to these conditions and it shows the 
requirements of these cells for homeostasis. It also shows that culture conditions can drastically 
change the metabolic profiles of tumor cells. The increase of NADPH and a-KG in cultured 
glioma cells suggests that the cells are trying to regulate their metabolomics by decreasing the 
relative ratio of 2HG to a-KG. By decreasing the ratio of 2HG compared to a-KG, the cells 
would be less inhibited by 2HG. Groups have shown that gliomas with the IDH1 mutation have 
decreased NADPH due to its consumption during IDH1R132H enzymatic activity 101. This 
further shows that culture conditions change the metabolic profile of the cells compared to them 
in their microenvironment. We also saw that glioma cells with mutated IDH1 had alterations in 
their TCA pathway, which other groups have also found 194,204. Both the cultured cells and tumor 
brains with IDH1R132H had increased 2HG as expected, which could have profound effects on 
gene expression and epigenetics.  
 The wildtype and IDH1R132H murine gliomas recapitulate the human proneural subtype 
by RNA sequencing as seen in human gliomas. We analyzed the differentially expressed genes 
by GSEA using the Barres transcriptomic analysis of cell types 11. Interestingly, although both 
the ID1R132H mutant tumors and wildtype tumors had no difference in OPC lineage gene 
expression, other lineages were changed. The wildtype tumors expressed fewer lineage-restricted 
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genes by having increased gene set enrichment of neuron, myelinating oligodendrocytes, 
astrocytes, and microglia. This suggests that the IDH1R132H mutation causes more lineage 
restriction in this tumor model. We hypothesize that this is due to increased H3K27me3 
restriction.     
 We found that glioma cells harboring the IDH1R132H mutation or wildtype cells treated 
with 2HG had increased H3K27me3. Furthermore, we found that cells treated with the EZH2 
inhibitor Tazemetostat, although not cytotoxic, reduced H3K27me3 and increased H3K27ac. 
These epigenetic changes on H3K27 were more profound over longer time courses showing the 
drug effectiveness is time-dependent. We previously found by RNA-sequencing that EZH2 
inhibition increased expression of Ndn (necdin). We found that in glioma cells treated with 
Tazemetostat for long periods of time, necdin levels were increased and that IDH1R132H cells 
had lower baseline levels. Necdin is primarily expressed in post-mitotic neurons and this 
suggests that removing the inhibitory mark H3K27me3 reduces lineage restriction. We can then 
reason that IDH1R132H glioma cells with increased H3K27me3 would be more OPC lineage-
restricted and thus have less necdin. We will perform further RNA-sequencing experiments on 




Chapter 3: The effect of EZH2 inhibitor and HDAC inhibitor on glioma 
cells and in slice culture 
 
 Brain tumors have high morbidity and mortality due to their location and diffuse nature. 
Gliomas are one of the most common primary brain tumors in adults 205. Treatment for patients 
with gliomas include surgical resection followed by chemotherapy and radiotherapy 206,207. This 
standard of care prolongs survival but is not curative 208. Due to the diffuse nature of gliomas, 
full surgical resection is not possible. Low-grade gliomas are relatively slow growing; however, 
they eventually progress to higher-grade gliomas and secondary glioblastomas which are more 
aggressive with poor survival.  
 IDH1R132H mutations occur in 80% of low-grade gliomas and secondary GBM 90. 
Unmutated IDH1 produces alpha-ketoglutarate (a-KG) from isocitrate in the tricyclic acid cycle. 
ID1R132H is a gain-of-function mutation which consumes a-KG to produce the oncometabolite 
2-hydroxyglutarate (2HG).  2HG is a competitive inhibitor of a-KG dependent dioxygenases 
including the Jumonji C (JmjC)-domain containing subfamily of Histone Lysine Demethylases 
(KDM). Two of such enzymes are Ubiquitously Transcribed Tetratricopeptide Repeats on the X 
Chromosome (UTX)/KDM6A and the functional isoform Jumonji Domain Containing 3 
(JMJD3)/KDM6B which specifically demethylate H3K27. H3K27me3 is a repressive mark that 
is thought to target lineage genes, and many neuron-specific genes that become activated upon 
terminal differentiation are repressed by H3K27me3 in progenitor cells 209. Enhancer of Zester 
Homolog 2 (EZH2) is the main writer for H3K27 trimethylation. It is the catalytic subunit of 
Polycomb Repression Complex 2 (PRC2).  EZH2 is overexpressed in multiple malignant cancer 
types by mediating H3K27me3 and promoting tumor growth and metastasis 210. Based on this, 
multiple drugs that inhibit EZH2 to reduce H3K27me3 are currently in clinical trials.  
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 We have found that our model of glioma cells is not sensitive to the cytotoxic effects of 
the EZH2 inhibitor Tazemetostat. However, we found that treatment with this drug reduced 
H3K27me3 and produced the reciprocal increase of H3K27 acetylation (H3K27ac). Histone H3 
lysine 27 acetylation is a gene enhancer mark. H3K27ac and H3K27me3 are antagonistic 211 as 
the same location on the histone tail cannot both be acetylated and trimethylated. Acetylation of 
this mark is associated with transcriptional activation and is enriched at regions of active 
enhancers 212 and super-enhancers 213,214. EZH2 inhibitor treatment has been shown to increase 
H3K27ac 198,215. Histone deacetylase inhibitors (HDACi) increase acetylation and have become a 
promising avenue for cancer treatment 216-219. HDACi have been shown to modulate H3K27ac 
220,221.  Due to the crosstalk between H3K27 methylation and acetylation, we and others have 
hypothesized that using a combination of EZH2 inhibitor with HDACi to treat cancer would be 
synergistic 222-224. In this chapter, I present the results of experiments testing this 
mechanistic/therapeutic hypothesis in a series of studies using glioma cell cultures and acute 
slice cultures generated from the IDH1R132H mouse glioma model. 
3.1 Results 
3.1.1 Tazemetostat sensitizes IDH1R132H cells to Panobinostat.   
 
 We found that our glioma cell model was insensitive to Tazemetostat but treatment 
increased H3K27ac. Based on these findings we wanted to see if Panobinostat, a pan-deacetylase 
inhibitor, would be an effective co-treatment. We pre-treated cells with DMSO or Tazemetostat 
and after 24 hours we added incremental doses of Panobinostat to see if EZH2 inhibition 
sensitizes glioma cells to Panobinostat (Figure 3.1A). IDH1R132H (IC50=47.64) cells were less 
sensitive to Panobinostat than wildtype (IC50=20.04) cells based on viability, however EZH2 
inhibition increased sensitivity for both cell types (WT IC50=17.65 and IDH1R132H 
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IC50=22.95). We repeated this experiment three times and did area-under-the-curve analysis 
(Figure 3.1B). IDH1R132H cells were significantly more viable with Panobinostat treatment and 
Tazemetostat significantly decreased survival in the wildtype and mutant glioma cells. This data 
shows there is significant synergy between Tazemetostat and Panobinostat. 
 
   
 To further determine if this drug co-treatment is synergistic, we calculated the coefficient 
of drug interaction (CDI) 24hour 100nM Panobinostat treatment (Figure 3.2B/C). The CDI was 
below 1 for both the wildtype (mean=0.61) and IDH1R132H (mean=0.64) demonstrating that the 
interaction between Tazemetostat and Panobinostat is synergistic for both cell lines. We also 
determined the CDI for the IDH1R132H mutation and Panobinostat and found is to be 1.5, 
showing an antagonistic relationship. This suggests that the IDH1R132H mutation causes glioma 

































































Figure 3.1 Glioma viability to Tazemetostat and Panobinostat co-treatment.  
A) Representative dose-response of wildtype and ID1R132H glioma cells from 
increasing dose of Panobinostat with or without 5uM Tazemetostat (EZH2i), given as 
pretreatment for 24 hours prior to addition of Panobinostat, and continued throughout 
treatment with Panobinostat (72 hours). Luminescence values normalized to untreated cells 
from Cell Titer Glo. B) Area-under-the-curve analysis from three independent viability 




3.1.2 Tazemetostat and Panobinostat co-treatment increase H3K27ac. 
 
 To determine the mechanism of action of Tazemetostat and Panobinostat, we treated cells 
with low drug doses for a shorter amount of time and looked at their epigenetic marks. Cells 
were pretreated with Tazemetostat or DMSO for 24 hours then retreated with the addition of 
Panobinostat or DMSO for 24 hours. These treatment conditions were designed to try to avoid 
cell death while still affecting their epigenetic landscape (Figure 3.3A). IDH1R132H glioma 
cells had increased H3K27me3 compared to wildtype as previously shown (Figure 2.6).  We saw 
that Tazemetostat significantly reduced H3K27me3 in both the wildtype and IDH1R132H 
glioma cells (Figure 3.3B). Interestingly, we found that cells treated with Panobinostat had 
increased H3K27me3 although this was not significant compared to control due to variability 






























































Figure 3.2 Tazemetostat and Panobinostat co-treatment are synergistic in glioma cells. 
Glioma cells were plated and pre-treated with Tazemetostat (5µM) for 24 hours then 
treated with Panobinostat (100nM) for an additional 24 hours in the presence of 
Tazemetostat. A) Representative 3-way ANOVA of wildtype and IDH1R132H glioma cells 
with multiple comparisons. Cells were plated and pre-treated with DMSO or Tazemetostat 
and then treated with DMSO or 100nM Panobinostat. Source of variation: Panobinostat 
(94.94% of variation, P<0.0001), IDH1R132H (0.8331% of variation, P=0.0234), Tazemetostat 
(0.9185% of variation, P=0.0182), Panobinostat x Tazemetostat (0.6019% of variation, 
P=0.0491). B) Coefficient of drug interaction from three independent experiments looking at 
Tazemetostat and Panobinostat synergy in wildtype and IDH1R132H cells normalized to 
DMSO. C) Coefficient of drug interaction from three independent experiments looking at the 
interaction of Panobinostat and IDH1R132H.   
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since, based on the IDH1R132H model (less sensitive) and Tazemetostat synergy (more 
sensitive), cells with less trimethylation appear to be more susceptible to Panobinostat-induced 
cytotoxicity. This may also account for the increased IDH1R132H levels found in treated cells 
(Figure 3.3F). If the treatments are selectively killing cells expressing low IDH1R132H, then we 
would expect to see an increase in IDH1R132H levels in the homogenate of treated cultures. 
Alternatively, the increase in IDH1R132H could reflect an epigenetically-regulated increase in 
IDH1R132H expression in the treated cell.  When glioma cells were treated with both 
Tazemetostat and Panobinostat, H3K27me3 returned to level similar to control (Figure 3.3B).   
Most notably, the co-treated cells significantly increased H3K27ac compared to control even 
though Panobinostat alone did not significantly increase acetylation (Figure 3.3C). This suggests 
that the mechanism of action of the co-treatment is to block methylation allowing for more 
acetylation than either single treatment alone. We also saw a decrease in Sox2 expression 
suggesting the co-treatment is preferentially targeting Sox2+ cells (Figure 3.3E). Necdin levels 
were also significantly increased in the Tazemetostat-treated and co-treated cells (Figure 3.3D). 
This decrease in Sox2 expression and a reciprocal increase in necdin (Figure 3.3D/E), may also 
reflect treatment-induced shift in cellular phenotype, which recapitulate the epigenetically-
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Figure 3.3 Western blot analysis of Tazemetostat and Panobinostat co-treatment on 
glioma cells.  
A) Representative western blot of wildtype and IDH1R132H glioma cells pre-treated 
with 5uM Tazemetostat (EZH2i) for 24 hours and then treated with 20 nM Panobinostat 
(HDACi) for an additional 24 hours in the presence of Tazemetostat. Cells were fractionated 
for the cytoplasmic fraction (CF) and nuclear fraction (NF) was acid extracted. Quantification 
of H3K27me3 B) and H3K27ac C) normalized to total H3. Quantification of Necdin D), Sox2 
E), and IDH1R132H F) normalized to actin. All bar graphs are from three independent 
experiments and shown as fold change to control. Students T-test used for statistical analysis.   
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 To further analyze the effect of co-treatment on the glioma cells, we performed flow 
cytometry. It is important to note: we did not control for total Histone H3 unlike for the western 
blots. We did not see an increase in H3K27me3 in the IDH1R132H cells, probably due to 
heterogeneity and cell-type-specific differences in total Histone H3. Tazemetostat decreased 
H3K27me3 and Panobinostat increased trimethylation (Figure 3.4A/B). The co-treatment 
brought H3K27me3 levels back to control levels. By flow cytometry, we saw that in both 
wildtype and IDH1R132H glioma cells Tazemetostat, Panobinostat and the co-treatment 
significantly increased H3K27ac (Figure 3.4C/D).  Tazemetostat increased it least, then 
Panobinostat and finally the co-treatment increased acetylation to almost 10-fold.  Notably, these 
trends are consistent with the results of the Western Blot analysis (Figure 3.3) and provide 
cellular resolution on the heterogeneity of these histone marks across the different treatment 
























































































































































Sample Name Percent 
Positive
Median Mean Mode
WT 49.6 2969 3964 3034
WT EZH2i 25.3 1777 2815 1456
WT HDACi 94.3 7512 10925 7237
WT EZH2i+HDACi 54.1 3240 5563 3448
IDH1R132H 50.8 3028 4799 2438
IDH1R132H EZH2i 14.5 952 2046 516
IDH1R132H HDACi 92.9 7834 12527 6516
IDH1R132H EZH2i+HDACi 45.2 2670 4869 2676
H3K27me3
Sample Name Percent 
Positive
Median Mean Mode
WT 6.95 2387 2967 1853
WT EZH2i 58.8 6308 7713 6294
WT HDACi 40.6 4965 6750 4334
WT EZH2i+HDACi 86.8 9773 13054 9620
IDH1R132H 15.1 2928 3666 3678
IDH1R132H EZH2i 54.3 6054 7965 6294
IDH1R132H HDACi 56.8 6253 8355 6294





























3.1.3 Co-treatment of acute slice culture of mouse gliomas increases H3K27ac and reduces 
tumor. 
 
 Based on our in vitro findings we wanted to see how our co-treatment would influence 
tumor cells in the context of the brain tumor microenvironment. We used organotypic slices 
generated from our IDH1R132H mouse gliomas to model the in vivo microenvironment. This 
method allows for multiple drug treatments ex vivo, while avoiding the challenges of 
intracerebral drug delivery and system toxicity. It also provides an experimental system in which 
these treatment conditions could be tested on acute slices generated from surgical samples of 
human glioma. Mice were injected with the IDH1R132H mutant glioma cells and monitored 
until tumor end-point. Slices were cut from the tumorigenic region (ipsilateral and contralateral) 
and treated with 10-fold higher doses of Tazemetostat and Panobinostat to ensure drug 
permeation to each slice. Slices were pretreated with Tazemetostat or DMSO for 24 hours then 
Panobinostat or DMSO was added for another 24 hours. Tazemetostat significantly reduced 
H3K27me3 in the slices (Figure 3.5B). Panobinostat treatment also increased H3K27me3 as we 
saw in the cell culture studies (Figure 3.5B).  There was notable within-group variability in the 
levels of H3K27ac after Panobinostat and co-treatment in slices, probably due to cell death 
(Figure 3.5C). There was a trend towards increase in H3K27ac after co-treatment, but this was 
Figure 3.4 Flow cytometry analysis of murine glioma cells with Tazemetostat and 
Panobinostat co-treatment.  
Cells were pre-treated with 5uM Tazemetostat (EZH2i) for 24 hours and then 20nM 
Panobinostat (HDACi) for an additional 24 hours in the presence of Tazemetostat. A) 
Representative flow cytometry analysis of H3K27me3 stained glioma cells. Table shows the 
percent positive cells based on dotted line, the median, mean, and mode. B) Quantification of 
H3K27me3 fold change to control from three independent experiments. C) Representative 
flow cytometry analysis of H3K27ac stained cells. Table shows the percent of positive cells 
based on dotted line (percent of cells to the right of dotted line), the median, mean, and 
mode. D) Quantification of H3K27ac fold change to control from three independent 
experiments. Student’s T-test performed as statistical analysis.    
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insignificant. We used PDGFRa as a marker for tumor cells and saw a decrease in all the drug 
treatments but most strikingly in the co-treatment condition, suggesting we are preferentially 
killing PDGFRa+ tumor cells in the slice (Figure 3.5D), although it is also possible that the 
treatment induced a down-regulation of PDGFRa expression.  To distinguish between these 
possibilities, we performed flow cytometry on PDGFRa+ cells (Figure 3.6). We also looked at 
IDH1R132H levels, as a marker that is selectively expressed in the tumor cells. We saw that the 
co-treatment also reduced IDH1R132H expression by an average of almost 50% (Figure 3.5E).  
Notably, this is in contrast to the increase in IDH1R132H seen in response to co-treatment in the 
cell culture experiments (Figure 3.3). The decrease in PDGFRa and IDH1R132H normalized to 
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 We also used flow cytometry to analyze the levels of H3K27me3 and H3K27ac 
specifically in the PDGFRa positive cells. This allowed us to look at epigenetic changes that are 
occurring in only the tumor cells. When we analyzed only the live tumor cells by gating on live 
cells that were PDGFRa-positive, we saw epigenetic changes that recapitulate our in vitro 
experiments. Tazemetostat decreased H3K27me3 levels and Panobinostat increased 
trimethylation (Figure 3.6A/B). H3K27ac was increased by each monotherapy but more so in the 
co-treatment (Figure 3.6C/D). Tazemetostat and Panobinostat had similar effects on the live 
tumor cells in the ex vivo slice as they did in vitro, supporting our mechanism of action that 
Tazemetostat allowed for more Panobinostat induced acetylation, causing more effective tumor 
cell death.  
Figure 3.5 Western blot analysis of Tazemetostat and Panobinostat co-treatment on 
IDH1R132H tumor slices.  
A) Representative western blot IDH1R132H tumor slices pre-treated with 50uM 
Tazemetostat (EZH2i) for 24 hours and then 200 nM Panobinostat (HDACi) for an additional 
24 hours in the presence of Tazemetostat. Cells were fractionated for the cytoplasmic fraction 
(CF) and nuclear fraction (NF) was acid extracted. Quantification of H3K27me3 B) and 
H3K27ac C) normalized to total H3. Quantification of PDGFRa D), and IDH1R132H F) 
normalized to actin. All bar graphs are from three independent experiments and shown as 





 The HDAC inhibitor Panobinostat has become a promising drug in the treatment of brain 
cancer. IDH1R132H mutations are common in glioma patients but this mutation has been shown 
to make tumors less sensitive to Panobinostat by us and others 226. Our mouse glioma model is 
also insensitive to the cytotoxic effects of the EZH2 inhibitor Tazemetostat although it does 
induce a significant increase in H3k27ac. We hypothesized that combining an HDAC inhibitor 
and an EZH2 inhibitor would be synergistic. EZH2 inhibitors remove H3K27me3 which allows 
H3K27me3
Sample Name Percent 
Positive
Median Mean Mode
IDH1R132H-cre 64.5% 22987 27576 33037
IDH1R132H-cre EZH2i 25.5% 8913 14550 8953
IDH1R132H-cre HDACi 58.3% 21820 31172 25277
IDH1R132H-cre EZH2i+HDACi 24.4% 8244 13355 10341
H3K27ac
Sample Name Percent 
Positive
Median Mean Mode
IDH1R132H-cre 24 18458 24799 17327
IDH1R132H-cre EZH2i 49.3 32099 38179 44981
IDH1R132H-cre HDACi 33.3 20327 32973 18676



































































































Figure 3.6 PDGFRa+  flow cytometry analysis of IDH1R132H brain tumors slices with 
Tazemetostat and Panobinostat co-treatment.  
IDH1R132H tumor slices were pre-treated with 50uM Tazemetostat (EZH2i) for 24 
hours and then 200nM Panobinostat (HDACi) for an additional 24 hours in the presence of 
Tazemetostat. A) Representative flow cytometry analysis of H3K27me3 stained cells. Table 
shows the percent positive cells based on dotted line, the median, mean, and mode. B) 
Quantification of H3K27me3 fold change to control from three independent experiments. C) 
Representative flow cytometry analysis of H3K27ac stained cells. Table shows the percent of 
positive cells based on dotted line (percent of cells to the right of dotted line), the median, 
mean, and mode. D) Quantification of H3K27ac fold change to control from three 
independent experiments. Student’s T-test performed as statistical analysis.    
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for increased H3K27ac. We further show that we can therapeutically take advantage of this 
secondary reciprocal effect of EZH2 inhibition by sensitizing cells to HDAC inhibitor. Using 
both Tazemetostat and Panobinostat increased H3K27ac more than either monotherapy and was 
significantly more cytotoxic to the cells.  
 Interestingly, we found that treating cells with Panobinostat alone at low-dose increased 
H3K27me3. Other studies have also seen the increase in H3K27me3 after HDAC inhibitor 
treatment in human lymphoblastoid cell lines 227 and Diffuse Midline Intrinsic Pontine Gliomas 
(DIPGs) 228.  The mechanism by which cells are able to increase their level of H3K27me3 after 
HDAC inhibitor treatment is not understood. However, it has been proposed that the increase in 
H3K27me3 can act a mechanism to protect cells from the effects of increased histone acetylation  
229., Furthermore, we found that inhibiting H3K27me3 with Tazemetostat sensitizes glioma cell 
to HDAC inhibitor induced cytotoxicity. This can be further expanded upon by looking at 
IDH1R132H mutant cells. The IDH1 mutation causes increased H3K27me3, and these cells are 
more resistant to Panobinostat treatment. Treating cells with the EZH2 inhibitor removes 
H3K27me3 to allow for Panobinostat to be more effective in both IDH1R132H and wildtype 
cells. EZH2 inhibitors also counteract the HDAC inhibitor-induced increase of H3K27me3.  
 To better understand the genetic changes the EZH2 and HDAC inhibitors cause on both 
glioma cell and OPCs, we will perform RNA sequencing of these cells in the different treatment 
conditions (in progress). This will show which genes are regulated by these enzymes. This could 
also show genetic changes that might increase H3K27me3 after Panobinostat treatment by 
comparing the Panobinostat treatment with cells treated with both Tazemetostat and 
Panobinostat. This could also show the mechanism by which Panobinostat and the co-treatment 
cause cell cytotoxicity.  The epigenetic changes induced by these drugs are thought to cause the 
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cell to upregulate specific genes that cause cell cycle arrest and cell death. Analyzing the gene 
expression changes by RNA sequencing will provide further insight into the cellular responses 
associated with treatment-induced cytotoxicity. To further analyze the epigenetic changes that 
the treatments induce in our cells, in future studies we will also perform ChIP-sequencing and 
pull-down H3K27me3 and H3K27ac. This will show exactly which genes are regulated by the 
drugs’ epigenetic effects on H3K27 and not by secondary drug effects.   
 We saw that treating glioma cell with a low dose of Panobinostat and the co-treatment 
cause an increase in relative IDH1R132H expression but slice cultured tumors treated with a 
higher dose had decreased IDH1R132H. The increase of IDH1R132H after low dose treatment 
could be due to selective killing of cells that express less IDH1R132H or due to an actual 
upregulation of IDH1R132H. The expression of IDH1R132H in both our glioma cells and OPCs 
is due to the retroviral infection which does not equally affect cells. Some cells express more 
IDH1R132H than others because of the infection method. Specifically, the levels of expression 
will depend on the number and location of the retrovirus insertion sites, which varies from cell to 
cell. It also could be that as we are changing the epigenetics of these cells, the retrovirus could be 
expressed more. Others have found that retroviruses are epigenetically silenced 230-232 and by 
influencing cellular epigenetic marks through drug treatments, we could be increasing 
IDH1R132H expression.  We saw that the IDH1R132H mutation is protective against 
Panobinostat-induced cytotoxicity, so it stands to reason that cells expressing less IDH1R132H 
would be more susceptible to drug treatment.  However, it is also possible that the epigenetic 
changes induced by drug treatment cause an increase in IDH1R132H expression. To determine 
which causes the increase of IDH1R132H we will perform flow cytometry on the cells. The 
IDH1R132H antibody has not been optimized for immunofluorescence or flow cytometry 
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however, a group recently found a method to analyze IDH1 status by flow cytometry 233. We will 
use this method to determine if selective killing or upregulation cause the increase of 
IDH1R132H in cells. The decrease of IDH1R132H in treated-slice-cultured samples correlate 
with a decrease in PDGFRa. We believe that this shows that our drug treatment is specifically 
targeting tumor cells in the slice. To better understand the therapeutic potential of this co-
treatment strategy, we will perform in vivo studies in our IDH1R132H mouse glioma model, 
using intratumoral convection-enhanced delivery of Tazemetostat and Panobinostat (in progress). 
In future studies, we will also perform co-treatment studies in acute slice cultures generated from 
surgical samples of human glioma, and compare the effects of this treatment in IDH1-mutant and 






Chapter 4: Characterize the effect of IDH1R132H and 2-
Hydroxyglutarate on oligodendrocyte progenitor cell metabolic and 
epigenetic status 
 
 Gliomas are the most common type of malignant primary tumor that arise from glial cells 
in the central nervous system. Molecular characterization of gliomas has allowed for the 
identification of subgroups that are phenotypically and genetically distinct 6. These subtypes 
include: proneural, mesenchymal, classical, and neural. Proneural glioma patients have better 
prognosis, are younger, and account for the majority lower grade gliomas (grade II and III) as 
well as a subset of GBM 26,234. Proneural gliomas are associated with amplification of PDGFRa, 
p53 deletion, and IDH1 mutations6. The IDH1 mutation that substitutes arginine 132 to histidine 
(IDH1R132H) is most common (greater than 90%) 38,94,235,236. The IDH1R132H mutation is an 
oncogenic gain-of-function mutation that produces the oncometabolite 2-hydroxyglutarate 
(2HG). Wildtype IDH1 produces alpha-ketoglutarate (aKG), which is important in multiple 
biological functions including nutrient oxidation, energy production and is a critical intermediate 
of the tricarboxylic acid cycle (TCA cycle)237. 2HG is an oncometabolite that acts as a 
competitive inhibitor of aKG-dependent enzymes, including the Jumonji C (JmjC)-domain-
containing subfamily of Histone Lysine Demethylases (KDM). Thus, the abnormal enzymatic 
activity of ID1R132H causes changes to cellular metabolism and epigenetic modifications 
25,204,238,239.  IDH1 mutated tumors develop specific genetic lesions during gliomagenesis (Figure 
1.1) with unique pathological progression 33,38,72,94. Gliomas with the IDH1R132H mutation are 
clinically distinct based on their localization (most common in frontal lobe) and age (most 
common in younger patients).  IDH1R132H tumors are primarily localized to the frontal lobe 
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while wildtype gliomas are more widespread 3,23,72. The frontal lobe is abundant in white matter 
in which oligodendrocyte progenitor cells (OPCs) primarily reside 60. OPCs are responsible for 
myelin regeneration and are the largest group of immature cycling cells in the brain 7. Proneural 
gliomas from both human and mice have a transcriptional expression profile that resembles 
OPCs and are enriched in OPC lineage markers 59,76,79,240. As such, proneural gliomas are thought 
to arise from transformed OPCs.   
 OPCs have the ability to proliferate and self-renew, or differentiate into myelinating 
oligodendrocytes 241,242. Oligodendrocytes that have differentiated from OPCs extend multiple 
processes that ensheath axons to form layers and compose myelin 243.  Myelinating 
oligodendrocytes are crucial for neural transmission maintenance and neuronal support 243. 
Undifferentiated OPCs express immature glial lineage marks, such as platelet-derived growth 
factor receptor alpha (PDGFRa) and neural/glial antigen 2 (NG2). They also represent the 
largest population of cycling cells in the adult brain (as high as ~5%) 7,43. Our lab and others 
have established the tumorigenic potential of OPCs residing in the adult white matter of mice 
and rats 5,7,66,76-79. Although OPCs have been thoroughly investigated, the effect of IDH1R132H 
mutation in cellular transformation has not been fully established. IDH1R132H mutations occur 
early in gliomagenesis suggesting that it drives tumor initiation 94,236. The effects of IDH 
mutations are context-specific, and since OPCs are a cell-of-origin of gliomas, and IDH1 is a 
first-initiation genetic alteration, then the glioma-initiating effects occur within the cellular 
context of normal or close-to-normal OPCs.  
 2HG competitively inhibits aKG-dependent dioxygenases such as the Histone H3 lysine 
27 (H3K37) demethylases UTX/KDM6A and JDJD3/KDM6B. We have shown that glioma cells 
with the IDH1R132H mutation have increased H3K27 trimethylation and are more lineage-
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restricted than wildtype glioma (Figure 2.4). EZH2 is the main writer for di- and tri-methylation 
of H3K27me3. EZH2 is highly expressed in OPCs but decreased when these cells differentiate to 
mature oligodendrocytes 11,244. Furthermore, EZH2 overexpression in neural stem cells increases 
differentiation into oligodendrocyte lineage and suppresses astrocyte differentiation245 suggesting 
H3K27me3 plays multiple complementary roles in inducing and maintaining an OPC state, 
including restricting progenitor cells to the oligodendrocyte lineage while also inhibiting 
oligodendrocyte differentiation. We hypothesize that IDH1R132H-mutated OPCs have increased 
H3K27me3, which keeps them undifferentiated and lineage-restricted. By retaining an immature 
phenotype and impairing normal development and lineage progression, OPCs could be more 
tumorigenic.  
 To better understand the effect of IDH1R132H on tumorigenesis we isolated murine 
OPCs. We used the EZH2 inhibitor Tazemetostat to focus on the influence of H3K27me3 in 
OPCs. As we previously showed in glioma cells, we do not expect Tazemetostat to be cytotoxic 
to cells, but it should have profound changes in gene expression. Using OPCs we are able to 
study key events that occur at the earliest stages of glial transformation within the specific 
cellular context in which they occur. 
4.1 Results 
4.1.1 2HG increases H3K27me3 in uninfected OPCs which EZH2i blocks 
 
 Several studies have found a correlation of patients with IDH1R132H with positive 
prognosis and improved survival outcome 32,91,246-250, however the prevalence of the mutation 
suggests it is a driver in gliomagenesis. We used OPCs to determine the influence of 2HG on 
untransformed cells. OPCs were isolated from p53fl/fl postnatal day 5 mice with stop-floxed 
mCherry luciferase by PDGFRa immune-panning 243,244 . These cells have intact p53 and 
 64 
wildtype IDH1 but only grow in culture for a very short amount of time (they stop expanding 
after 3 passages) without being infected with a cre-expressing virus to delete p53. In cell culture 
systems, OPCs stop proliferating after a limited number of divisions and differentiate into 
postmitotic oligodendrocytes 251,252. Deleting the tumor suppressor p53 is sufficient to transform 
OPCs so that they continue to proliferate in cell culture conditions 253. Cells were plated and pre-
treated with Tazemetostat for 16 hours then treated with 2HG for 24 hours (in the continued 
presence of Tazemetostat). Cells were harvested and fractionated for the cytoplasmic and nuclear 
fractions; the nuclear fraction was acid extracted to isolate histones (Figure 4.1A). When treated 
with 2HG the uninfected OPCs had increased H3K27me3 which Tazemetostat prevented (Figure 
4.1B). Uninfected OPCs have reduced proliferation compared to p53-deleted OPCs and glioma 
cells, which could explain the decreased effect of Tazemetostat (only about 50% reduction 
compared to about 75-90% reduction in glioma cells). H3K27ac was increased in all samples 
compared to control, however only the 2HG was significant. This suggests a complicated 
crosstalk between H3K27ac and trimethylation in which the cells are trying to restore 
homeostasis.  
 We previously found that metabolically-stressed glioma cells treated with Tazemetostat 
have increased expression of Ndn (Figure 2.9) and that treating glioma cells in culture increases 
necdin protein expression (Figure 3.3). Based on these findings we wanted to see if necdin is 
increased in OPCs as well. We found that Tazemetostat treatment increased necdin levels in 
uninfected OPCs (Figure 4.1B). We tried to analyze OPCs by immunofluorescence however this 
was too difficult. OPCs need to be very confluent to proliferate, which makes them difficult to 
stain by immunofluorescence. The OPCs will not grow if they are not confluent enough, or they 




4.1.2 OPCs infected with IDH1R132H retrovirus proliferate faster but lose the mutation over 
time  
 
 To determine the influence of IDH1R132H in early transformation we infected primary 
cell cultures of OPCs in vitro with IDH1R132H expressing retrovirus. We compared lysates 
from infected OPCs to determine if OPCs increase 2HG when IDH1R132H is mutated and have 
similar metabolic changes compared to fully transformed glioma cells. OPCs were isolated from 
mcherry-luciferase stop-flox p53 flox/flox mice then infected with a retrovirus expressing cre alone to 
delete p53 or with cre and IDH1R132H. We used this model because mouse OPCs will not grow 
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Figure 4.1 In uninfected OPCs, 2HG increases H3K27me3, which EZH2i blocks.  
A) Western blot of uninfected OPCs treated with 5µM Tazemetostat (EZH2i) for 16 hours then 
treated with octyl-R-2HG (100uM) for 24 hours in the continued presence of Tazemetostat. Cells 
were fractioned for cytoplasmic fraction (CF) and the nuclear fraction was acid extracted (NFA). 
B) Quantification of H3K27me3 and H3K27ac normalized to H3 on the top. Quantification of 
Necdin normalized to actin on the bottom. Bar graphs are from three independent experiments 
and statistical analysis from student’s T-test. Error bars shown as standard error mean.  
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for long in culture if they continue to express p53, however these are not from a tumor and do 
not overexpress PDGF. OPCs infected with the IDH1R132H retrovirus expressed the mutant 
protein but we saw changes in protein expression and proliferation as they were cultured. After 
the cells were infected, we monitored their mCherry fluorescence to make sure they select for 
cells in which p53 is deleted. The infected OPCs will outgrow the uninfected OPCs, and the 
uninfected OPCs normally strop proliferating by passage 3. Between passage 3 and 5, the 
IDH1R132H OPCs grow faster than the IDH-wildtype OPCs (Figure 4.2). After passage 5, the 
IDH1R132H cells slow down and proliferate slower than the X-cre OPCs and when passage 5 
and 7 are included in the cell count, the difference is no longer significant.  
 
 
 We hypothesize that there would be protein expression and epigenetic mark changes that 
coincide with the reduction in proliferation found in IDH1R132H-cre expressing OPCs. We 
previously found that Tazemetostat is not toxic to the cells, so we cultured cells in either DMSO 


























Figure 4.2 IDH1R132H-cre infected OPCs grow faster than X-cre infected OPCs.  
A) Stop-floxed mCherry OPCs were infected with X-cre or IDH1R132H-cre 
retroviruses then allowed to grow until all cells expressed mCherry (passage 3). Cells were 
plated and the fold change calculated after 6-7 days based on cell count for passages 3 to 5. 
Paired T-Test used for statistical analysis. B) Microscope picture of passage 4 X-cre and 
IDH1R132H-cre OPCs one day after plating the same number of cells.  
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or Tazemetostat to see the effect of chronic treatment. OPCs were grown continuously in DMSO 
or Tazemetostat and passaged once per week for seven passages (Figure 4.3A). OPCs harvested 
from passage 3, 5 and 7 were fractionated to look at histone marks as well as IDH1R132H and 
necdin levels (Figure 4.3B). As IDH1R132H-cre infected OPCs were cultured, their levels of 
IDH1R132H were reduced (Figure 4.3C). This reduction was not changed by Tazemetostat 
treatments, suggesting it is not regulated by H3K27me3. This could be due to selection of OPCs 
with low IDH1R132H expression or by gene silencing. In this in vitro culture setting, OPCs 
downregulate IDH1R132H expression between passage P3 and P7 (Figure 4.3). Notably, 
analysis of human tumor tissue has shown that IDH1R132H is retained during gliomagenesis and 
glioma progression from low-grade to high-grade glioma 82.  Similarly, IDH1R132H expression 
is maintained during gliomagenesis in our mouse glioma model (described in chapter 2), which 
introduces the same set of genetic alterations into (presumably) the same cells in vivo. This 
suggests that culture conditions either induce or select for reduced levels of IDH1R132H protein, 
and this process does not occur in the brain tumor microenvironment. To overcome this 
experimental obstacle, we continuously measured IDH1R132H expression and only used low 
passage OPCs for the following experiments.  
 Necdin levels are reduced in the IDH1R132H glioma cells and we found that infecting 
OPCs with IDH1R132H-cre also reduced necdin levels (Figure 4.3C, middle). Treatment with 
Tazemetostat increased necdin levels in the OPCs as seen in glioma cells. The nuclear fraction as 
acid extracted for histone isolation. IDH1R132H-cre cells have increased H3K27me3 (passage 3) 
but when the OPCs lose the mutation (passage 7), their H3K27me3 levels are decreased as well 
(Figure 4.3C, bottom). This shows that the increase in H3K27me3 is directly caused by 
IDH1R132H expression.  Tazemetostat treatment was found not to kill OPCs after chronic 
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culture but continues to reduce H3K27me3 levels. Also, H3K27ac increased with chronic 
Tazemetostat treatment and this was retained over the experimental time course. This experiment 
was only completed one time and would need to be repeated for verification.  
 
4.1.3 IDH1R132H infected OPCs have increased 2HG 
 
 We measured the infected OPC metabolites to determine if 2HG was increased in the 
mutant OPCs and to see what other pathways were altered. IDH1R132H mutant OPCs had 51 
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Figure 4.3 IDH1R132H-cre infected cells reduce IDH1R132H protein levels. 
A) Time course of experiment. Cells were passaged once a week and 1x106 cells were 
plated in Tazemetostat (5uM) or DMSO. Cells were re-treated every other day for the course of 
the experiment. B) Western blot of x-cre and IDH1R132H-cre infected cells for passage 3, 5 and 
7. Cells were fractionated for cytoplasmic fraction (CF) and the nuclear fraction was acid 
extracted (NFa). The histones for untreated passage 5 IDH1R132H-cre were lost in processing 





and α-KG (Figure 4.4A/B).  We performed metabolite pathway analysis on these metabolites and 
found that only 2 pathways were significantly altered (Figure 4.4C). One of the pathways was 
the TCA cycle with pyruvate, cis-aconitate, and α-KG being increased in IDH1R132H mutant 
OPCs. Again, other pathways which utilize α-KG were altered, including arginine biosynthesis 
and the alanine, aspartate and glutamate metabolism pathways. Together this data suggests that 
IDH1R132H increases both 2HG and α-KG significantly in OPCs and glioma cells (Figure 2.3). 
The increase in α-KG is possibly a response to rectify the increase in 2HG and we hypothesize 



























































Status p -log(p) Holm p FDR Impact
Arginine biosynthesis 5/14 3.87E-05 10.159 0.003253 0.003253 0.28934
Neomycin, kanamycin and 
gentamicin biosynthesis 2/2 9.54E-04 6.955 0.079172 0.040063 0
Amino sugar and 
nucleotide sugar 
metabolism 5/37 0.00491 5.3165 0.40261 0.12995 0.03921
Pyrimidine metabolism 5/39 0.006188 5.0851 0.50125 0.12995 0.11311
Alanine, aspartate and 
glutamate metabolism 4/28 0.009841 4.6212 0.78726 0.13949 0.04808
Starch and sucrose 
metabolism 3/15 0.009964 4.6088 0.78726 0.13949 0.49833
Purine metabolism 6/66 0.014654 4.223 1 0.17585 0.13346
Citrate cycle (TCA cycle) 3/20 0.022378 3.7997 1 0.23496 0.15493





Figure 4.4 Metabolomic analysis of X-cre and IDH1R132H-cre infected OPCs. 
A) Heatmap of significantly different metabolites based on students T-test comparing 
wild-type and IDH1R132H OPCs. Color scale intensities represent z-score for higher expression 
(dark blue) and lower expression (light blue). B) Bar graph showing peak metabolite expression 
of a-ketoglutarate and 2-hydroxyglutarate with student’s T-test statistical analysis. C) Pathway 
analysis of significantly different metabolites from students T-test using MetaboAnalyst 4.0 10. 




4.1.4 P53-deleted OPCs do not form tumors in mice 
 
 To determine if these OPCs that were infected in vitro are tumorigenic, we injected mice 
with passage 5 OPCs, which expressed mCherry as a reporter of retroviral infection. We injected 
mice from the same line that the OPCs were made from: p53fl/fl ; LSL-mCherry Luciferase. Mice 
were monitored by IVIS luciferase imaging. We saw that at 14 days post-injection (DPI) there 
appeared to be some OPCs, but over time these cells diminished and there was no signal in any 
of the mice by 94 DPI (Figure 4.5).  This suggests that while deletion of  p53 was sufficient to 
keep OPCs in a proliferative state in vitro when grown in growth factor containing media (PDGF 
and bFGF), OPCs require additional alterations to become fully transformed and capable of 
forming tumors in vivo. Our previous studies have shown that infecting OPCs with PDGF-











Figure 4.5 Luciferase imaging of mice injected with infected OPCs. 
Mice were injected with 50,000 OPCs infected with X-cre or IDH1R132H-cre 
retroviruses in vitro. Mice were monitored by IVIS luciferase imaging for tumor growth.  
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4.1.5 Infected OPCS treated with Tazemetostat have decreased H3k27me3 and increased 
H3K27ac   
 
 We wanted to see if infected OPCs followed the same pattern of epigenetic alterations as 
the glioma cells, as we hypothesize that IDH1R132H is context-specific in driving OPC 
tumorigenesis. We repeated 2HG and Tazemetostat treatment time courses in the wildtype and 
IDH1R132H OPCs between passage 3 and 6 (Figure 4.6A). In the OPCs, 2HG did not 
significantly increase H3K27me3, whereas OPCs expressing the IDH1 mutation had about a 
threefold increase in H3K27me3 (Figure 4.6B left) . Tazemetostat significantly decreased 
H3K27me3 in all samples.  All samples had increased H3K27ac compared to wildtype control 
(Figure 4.6B right). Furthermore, Tazemetostat significantly decreased H3K27me3, and 
increased H3K27ac in both the wildtype and IDH1R132H OPCs. We also found that EZH2 
inhibition only significantly increased necdin in 2HG-treated OPCs, but we saw a decrease in 
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4.1.6 Tazemetostat sensitizes infected OPCs to Panobinostat 
 
 We found that Tazemetostat and Panobinostat are synergistic in glioma cells (Chapter 3). 
To determine if Tazemetostat and Panobinostat have the same effect on OPCs, we repeated the 
co-treatment survival in wildtype- and IDH1R132H-mutated p53-deleted OPCs. The 
IDH1R132H-mutated cells were less sensitive to Panobinostat (Figure 4.7A/B), further 
suggesting mutated IDH1 protects cells from Panobinostat triggered cell death (WT IC50=15.72 
vs IDH1R132H IC50=23.65). We saw a similar trend for cells pre-treated with Tazemetostat, 
however the difference in sensitivity was less pronounced (WT IC50=11.5 and IDH1R132H 
IC50=13.28). More importantly, both wildtype and IDH1R132H mutant OPCs were more 
sensitive to the co-treatment than Panobinostat alone (Figure 4.7A/B). We repeated the survival 
study three times and found that EZH2 inhibition consistently and significantly lowers the area-
under-the-curve for both IDH1 WT and IDH1R132H glioma cells, and notably, the IDH1R132H 
mutated cells showed a trend towards being less sensitive to Panobinostat in the absence of 
Tazemetostat (p=0.074), but this trend was nearly abolished when cells were co-treated with 
Tazemetostat (Figure 4.7B).  
Figure 4.6 Infected OPCS treated with Tazemetostat have decreased H3k27me3 and 
increased H3K27ac.  
A) Western blot of OPCs infected with X-cre or IDH1R132H-cre retrovirus and pre-treated 
with 5µM Tazemetostat (EZH2i) for 16 hours then treated with octyl-R-2HG (100 uM) for 24 hours 
in the continued presence of Tazemetostat. Cells were fractionated for the cytoplasmic fraction 
(CF) and nuclear fraction (NF) which was then acid extracted. B) Quantification of H3K27me3 and 
H3K27ac normalized to total H3 as well as necdin normalized to actin. Bar graphs are shown as 





 We performed co-efficient of drug interaction analysis to determine if Tazemetostat and 
Panobinostat are synergistic. Both the wildtype (mean=0.42) and IDH1 mutant (mean=0.46) 
OPCs had an average CDI lower than 1, suggesting they are synergistic (Figure 4.8B). We also 
calculated the CDI for the IDH1 mutation and found the mean to be 1.3 (Figure 4.8C), further 
suggesting that IDH1R132H protects against the cytotoxic effects of Panobinostat in OPCs. 
Together this data demonstrates that the IDH1R132H mutation makes OPCs more resistant to 


















































































Figure 4.7 OPC viability to Tazemetostat and Panobinostat co-treatment.  
A) Representative dose-response curve of X-cre and ID1R132H-cre retrovirally 
infected OPCs from increasing dose of Panobinostat for 72 hours with or without 5uM 
Tazemetostat (EZH2i) 24-hour pre-treatment. Luminescence values are normalized to 
untreated cells from Cell Titer Glo. B) Area under the curve analysis from three independent 
viability experiments normalized to wildtype cells. Paired T-test is performed for statistical 
analysis.   
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4.1.7 Tazemetostat and Panobinostat co-treatment increase H3K27ac in infected OPCs. 
 
 We also looked at the epigenetic changes that the co-treatment had on p53-deleted OPCs 
(Figure 4.9A). When looking at the H3K27me3 levels, IDH1R132H OPCs had more baseline 
trimethylation than the wildtype, as we previously saw (Figure 4.3). Tazemetostat decreased 
trimethylation for both cell types (x-cre infected OPCs vs IDH1R132H-cre infected OPCs) and 
Panobinostat significantly increased trimethylation compared to Tazemetostat (Figure 4.9B). The 
Panobinostat treatment did not cause a significant H3K27me3 increase compared to control, due 
to variability. The increase of H3K27me3 after Panobinostat could reflect a preferential killing of 
cells with low H3K27me3. Similar to the glioma cells (Figure 3.3), the co-treatment increased 
IDH1R132H expression in OPCs (Figure 4.9F). This is may reflect differential sensitivity of 
cells with low IDH1R132H expression, and corresponding low H3K27me3. Treating cells with 
both Tazemetostat and Panobinostat brought the H3K27me3 levels to around base level with no 
significant difference between OPCs infected with x-cre vs IDH1R132H-cre (Figure 4.9B). The 
OPCs also had a marked increase in H3K27ac after treatment with both Tazemetostat and 
Panobinostat, with a 66.2- and 55-fold change for wildtype and IDH1R132H respectively (Figure 
4.9C). Notably, this effect is more pronounced in the OPCs than was seen in glioma cells 
exposed to the same treatments (Figure 3.3). This suggests OPCs may be even more sensitive to 
Figure 4.8 Tazemetostat and Panobinostat co-treatment are synergistic in OPCs. 
A) Representative 3-way ANOVA of X-cre and IDH1R132H-cre infected OPCs with 
multiple comparisons. Cells were plated and pre-treated with DMSO or Tazemetostat (5uM) 
for 24 hours and then co-treated with DMSO or 16nM Panobinostat for 72 hours. B) 
Coefficient of drug interaction from three independent experiments looking at Tazemetostat 
and Panobinostat synergy in wildtype and IDH1R132H cells. C) Coefficient of drug 
interaction from three independent experiments looking at synergy between Panobinostat 
and IDH1R132H (not treated with Tazemetostat).  
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Panobinostat than the glioma cells with respect to the synergistic effects of Tazemetostat and 
Panobinostat in increasing H3K27ac.  
 Tazemetostat monotherapy increased necdin expression (Figure 4.9D). The co-treatment 
or Panobinostat only reduced Sox2 expression significantly in all conditions, except for 
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 To further validate our findings, we performed flow cytometry on the OPCs. 
IDH1R132H-mutant OPCs showed increased H3K27me3 (Figure 4.10A/B), similar to the 
western blots. Tazemetostat significantly reduced H3K27me3 and Panobinostat significantly 
increased H3K27me3 in both cell types (Figure 4.10A/B), similar to the effects seen in the 
glioma model (Figure 3.4). H3K27ac was increased to progressively higher levels by 
Tazemetostat, Panobinostat and then by co-treatment in both wildtype and IDH1R132H mutant 
OPCs (Figure 4.10C/D). Together, these results suggest that Tazemetostat and Panobinostat co-
treatment is synergistic by increasing H3K27ac more than either monotherapy. 
Figure 4.9 Western blot analysis of Tazemetostat and Panobinostat co-treatment on 
OPCs with or without IDH1R132H mutation.  
A) Representative western blot of X-cre and IDH1R132H-cre retrovirally infected 
OPCs pre-treated with 5uM Tazemetostat (EZH2i) for 24 hours then treated with 20nM 
Panobinostat (HDACi) for 24 hours in the continued presence of Tazemetostat. Cells were 
fractionated for the cytoplasmic fraction (CF), and nuclear fraction (NF) was acid extracted. 
Quantification of H3K27me3 B) and H3K27ac C) normalized to total H3. Quantification of 
Necdin D), Sox2 E), and IDH1R132H F) normalized to actin. All bar graphs are from three 
independent experiments and shown as fold change to control. Students T-test used for 






4.2 Discussion  
 OPCs are the proposed cell of origin of proneural gliomas, including IDH1-mutated 
gliomas. To study the effects of IDH1R132H in the context of untransformed OPCs we isolated 
OPCs from postnatal transgenic mice (p53flox/flox, mcherry-luciferase stop-flox) and transfected in 
vitro to express IDH1R132H and delete p53. OPCs that express mutated IDH1R132H proliferate 
H3K27me3
Sample Name Percent 
Positive
Median Mean Mode
X-cre 62.4% 11719 21328 10723
X-cre EZH2i 22.4% 3777 9185 2676
X-cre HDACi 87.1% 21563 34495 17988
X-cre EZH2i+HDACi 28.6% 5313 11531 3678
IDH1R132H-cre 75.2% 17006 31860 17988
IDH1R132H-cre EZH2i 25.1% 4831 10636 4334
IDH1R132H-cre HDACi 81.8% 28889 46086 252680






















































































































































Sample Name Percent 
Positive
Median Mean Mode
X-cre 11.3% 1405 2631 943
X-cre EZH2i 55.3% 5750 11167 6080
X-cre HDACi 77.9% 9707 16443 7237
X-cre EZH2i+HDACi 89.9% 25702 41152 24334
IDH1R132H-cre 26.7% 2634 4944 2156
IDH1R132H-cre EZH2i 80.5% 9817 17022 7237
IDH1R132H-cre HDACi 82.6% 18545 30342 20911



























Figure 4.10 Flow cytometry analysis of OPCs with Tazemetostat and Panobinostat co-
treatment.  
X-cre and IDH1R132H-cre retrovirally infected OPCs were pre-treated with 5uM 
Tazemetostat (EZH2i) for 24hours then treated with 20nM Panobinostat (HDACi) for 24 
hours in the continued presence of Tazemetostat. A) Representative flow cytometry analysis 
of H3K27me3 stained cells. Table shows the percent positive cells based on dotted line, the 
median, mean, and mode. B) Quantification of H3K27me3 fold change to control from three 
independent experiments. C) Representative flow cytometry analysis of H3K27ac stained 
cells. Table shows the percent positive cells based on dotted line, the median, mean, and 
mode. D) Quantification of H3K27ac fold change to control from three independent 
experiments. Student’s T-test performed as statistical analysis.    
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faster than OPCs with wildtype IDH1. Over the course of several passages the OPCs showed 
reduced expression of IDH1R132H and their proliferation was reduced. Notably, these cells are 
not fully transformed and did not form tumors after injection into mice. Clinically, the 
IDH1R132H mutation is retained throughout gliomagenesis and tumor progression. Similarly, 
the IDH1R132H transgene was retained throughout gliomagenesis in our in vivo mouse model 
(chapter 2), showing that the effects of IDH1R132H in OPC transformation is different in the in 
vitro model. Notably, other labs have encountered challenges in generating primary cultures of 
IDH1-mutated glioma cells and have seen cells lose the mutation in vitro as well. I hypothesize 
cell culture systems place OPCs under metabolic stress which selects against cells that express 
high levels of IDH1R132H. As one approach to testing this hypothesis, we will treat cells with 
ROS reducing compounds, (such as contained in SATO media) to see if the cells are able to 
retain IDH1R132H expression. To better understand this, we will also use IDH1R132H knock-in 
OPCs and see if they also lose the mutant protein when it is not overexpressed.  
 These experiments also shows there is a difference in glioma cells, which retain 
IDH1R132H expression and OPCs. To better understand these differences, we have submitted 
OPC and glioma cells for RNA-sequencing. We will compare the glioma cells and OPCs to 
determine what the differences are by protein expression, metabolomics and epigenetics. We will 
further explore this by infecting OPCs with the growth factor PDGF. Notably, recent work by 
Dr. Angeliki Mela has shown that OPCs transformed in vitro with cre-mediated deletion of p53 
and overexpression of the PDGF ligand form tumors when injected into the subcortical white 
matter of mice. She also found that IDH1R132H knock-in OPCs infected with PDGF-IRES-cre 
were able to grow tumors after being injected into mice. In vitro studies with such cells will 
allow us to characterize the effects of IDH1R132H in more transformed OPCs and determine if 
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they retain the IDH1R132H mutation in vitro. This will allow us to characterize the metabolic 
and epigenetic alterations that the IDH1R132H mutation causes during cell transformation.   
 Treating uninfected OPCs with 2HG or transfecting OPCs with IDH1R132H increased 
H3K27me3. The EZH2 inhibitor Tazemetostat significantly reduced H3K27 trimethylation in 
OPCs as previously seen in glioma cells. Also, Tazemetostat treatment increased H3K27ac in 
transfected cells. Together, these findings demonstrate that these genetic and pharmacological 
perturbations are causing epigenetic alterations in OPCs that are similar to those seen in the 
proneural glioma cells.  
 In glioma cells, we found that necdin levels were decreased in IDH1R132H-mutated cells 
(Figure 2.10). OPCs transfected with IDH1R132H expressing retrovirus also had decreased 
necdin (Figure 4.3). This supports the idea that the reduction in necdin is due to the epigenetic 
effects of IDH1R132H expression. Also, treating OPCs with Tazemetostat shows a trend toward 
increased necdin, similar to the glioma cells, providing further evidence that necdin is regulated 
by H3K27me3 in OPCs. To further establish this connection, we will perform ChIP-PCR on 
OPCs to show that H3K27me3 directly regulates necdin expression.  
 Co-treatment with Tazemetostat and Panobinostat was synergistically cytotoxic to 
retrovirally-infected OPCs. IDH1R132H was found to protect OPCs from the cytotoxic effects of 
Panobinostat, but this protective effect was overcome by co-treatment with Tazemetostat. This is 
similar to the synergistic effects seen when we treated the proneural glioma cells with 
combinations of Tazemetostat and Panobinostat (chapter 3). This data suggests that Tazemetostat 





Chapter 5: Conclusions and Future Directions 
 
 Through this thesis I explored the influence of epigenetics in gliomagenesis. Tumors that 
harbor the IDH1R132H mutation and wildtype tumors are histopathologically similar, however 
there are important differences in genetic, epigenetic and gene-expression alterations. Patients 
with tumors that harbor the IDH1R132H mutation are highly enriched in the proneural glioma 
subtype  6,59. OPCs are considered the cell of origin for proneural gliomas due to their 
transcriptional and phenotypic similarities. The IDH1R132H mutation is an early genetic 
alteration in proneural glioma development, suggesting it is a tumor-initiating event. Therefore, 
we reason that OPCs provide the initial cellular context in which the tumor-initiating effects of 
IDH1-R132H are playing out 
 Throughout this thesis we used glioma cells and OPCs infected retrovirally to express 
IDH1R132H. It is important to note that this experimental system recapitulates some key aspects 
of the clinical scenario, but also differs in some potentially important ways. Notably, patients’ 
glioma samples are heterozygous for the mutant allele, while the mouse tumors are homozygous 
for the wild-type IDH1 allele and express the mutant allele from the retroviral insertion site(s). 
Thus, in our IDH1R132H mouse glioma model,  the relative abundance of the wild-type and 
mutant alleles may differ from what occurs in the human disease. This may have significant 
metabolic consequences since, the altered enzymatic activity results for heterodimers composed 
of both mutant and wildtype IDH1 96. To address this issue, we have developed a new 
experimental model by injecting PDGF-IRES-cre retrovirus into the subcortical white matter of 
transgenic mice that are heterozygous  for a  IDH1R132Hstop-flox 254 and homozygous for p53 flox-
flox. Thus, the retrovirus-transformed cells are heterozygous IDH1R132H, and expression of both 
the wild-type and mutant alleles are regulated by the endogenous promotors and (presumably) 
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subject to the same local epigenetic regulation. We are currently using this new IDH1R132H 
knock-in model to study the epigenetic and metabolic alterations that occur during proneural 
gliomagenesis.  
 We saw that gliomas with mutated IDH1 are more OPC lineage-restricted than wildtype 
gliomas which express more neuronal, astrocytic, myelinating oligodendrocyte and microglial 
genes. While this analysis of tumor tissue is confounded by potential differences in the relative 
abundance of neoplastic and non-neoplastic cell types in the IDH1-mutated versus IDH1-WT 
tumors, our results from the cell culture studies suggest that the observed differences in 
expression of lineage genes are tumor-cell-intrinsic and result from IDH1R132H-induced effects 
on H3K27me3.  We found that treating glioma cells with the EZH2 inhibitor causes decreased 
H3K27me3 and less lineage restriction, as seen by the increased expression of genes normally 
expressed in other (non-OPC) lineages. This supports the model in which increased H3K27me3 
causes more lineage restriction, i.e., IDH1R132H mutant tumors, and where reduced H3K27me3 
decreases lineage restriction, i.e., Tazemetostat treatment. We have submitted wildtype and 
IDH1R132H-expressing glioma cells and OPCs treated with Tazemetostat for RNA sequencing 
to expand upon this idea and better understand the effects of H3K27me3 on lineage restriction in 
this culture system.  
 Notably, within the context of our experimental system, Tazemetostat has no effect on 
viability which provides us the opportunity to use Tazemetostat as a pharmacological tool to 
further explore the effects of H3K27me3 on OPC and proneural glioma lineage restriction. Both 
OPCs and glioma cells were able to survive and proliferate in culture with Tazemetostat 
treatment for multiple weeks. In future studies, we could measure the transcriptional and 
epigenetics effects long-term Tazemetostat treatment has to determine the cellular phenotype in 
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culture. We could also test the effects of chronic Tazemetostat treatment on glioma growth in 
vivo and characterize the epigenetic and phenotypic effect. We could assess if H3K27 
methylation and acetylation is coupled in vivo as we previously saw in our in vitro studies 
(Tazemetostat increases H3K27ac) This would allow us to further assess if Tazemetostat alters 
the OPC-like transcriptional phenotype of glioma cells in vivo. 
 We found that cells treated with Tazemetostat had increased H3K27ac. To exploit the 
crosstalk between acetylation and trimethylation on H3K27, we treated cells with both 
Tazemetostat and the HDAC inhibitor Panobinostat. We found that this co-treatment was 
synergistic, with Tazemetostat sensitizing cells to Panobinostat. Interestingly, we also found that 
IDH1R132H-mutated cells were more resistant to Panobinostat-induced cytotoxicity. 
IDH1R132H cells have increased H3K27me3 which could be protective by preventing 
acetylation, since one residue cannot be both acetylated and trimethylated. This relationship may 
also explain why cells treated with Panobinostat have increased IDH1R132H. Cells that express 
less IDH1R132H would have less H3K27me3 and be more susceptible to Panobinostat treatment 
thus the treatment could be selectively killing cells with low IDH1R132H. We also saw that cells 
treated with Panobinostat had increased H3K27me3, which might result from selective killing of 
cells with relatively low H2K27me3. Cells with higher H3K27me3 levels may be less sensitive 
to the cytotoxic effects of Panobinostat. Alternatively, Panobinostat could cause a shift in the 
relative rates of methylation and demethylation, resulting in a net increase in H3K27me3.  These 
possibilities could be further explored by flow cytometry, with cell death markers, to determine 
if the increase of IDH1R132H in Panobinostat and co-treatment samples is due to an entire shift 
of the population by increased expression, or due to selective killing of cells with low levels of 
IDH1R132H. We could also use flow cytometry with cell death markers and H3K27me3 to 
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assess if levels of H3K27me3 correlate with sensitivity to Panobinostat.  Future studies could use 
ChIP-sequencing and RNA-sequencing to determine which genes are directly regulated by 
H3K27 and correlate the epigenetic and transcriptional effects of these drugs on IDH1-mutant 
and wildtype cells. 
 Based on our promising co-treatment data we will perform in vivo experiments. Although 
Tazemetostat has shown good brain penetration, the accumulation of drug is limited by the P-
glycoprotein ATP-binding cassette drug efflux pumps (ABCB1 and ABCG2) 255.  Panobinostat 
on the other hand does not cross the blood-brain barrier. To circumvent these problems that 
would prevent drug accumulation at the tumor site, we will use convection-enhanced delivery 
(CED). CED is a method of direct intraparenchymal drug administration to the brain through 
surgically implanted microcatheters. Local delivery is driven by hydrostatic pressure gradient 
from prolonged low-rate infusion. CED allows for precisely controlled infusion to the 
peritumoral tissue to provide relatively constant drug concentration and distribution 256-261. All 
CED treatments will be supplemented with gadolinium contrast enhancement to make sure there 
is good drug distribution, as monitored by MRI. We tested this approach by treating mice 
injected with IDH1R132H-mutant tumor cells with gadolinium alone or gadolinium with 350µM 
Tazemetostat (based on calculated brain concentration from systemic delivery 255,262) using 7-day 
pumps. Before the end of the treatment cycle (day 6), mice were sacrificed to evaluate their 
epigenetic marks to make sure that Tazemetostat reduces H3K27me3. We found that 
Tazemetostat significantly reduced H3K27me3 in our in vivo system (Figure 5.1).  
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 After establishing conditions in which these drugs have the expected epigenetic effect on 
mouse brain tumors, we will perform a survival experiment. Mice again will be injected with 
IDH1R132H mutant tumor cells and treated with gadolinium alone, 1µM Panobinostat, or 1µM 
Panobinostat and 350µM Tazemetostat. We hypothesize that Panobinostat will increase overall 
survival but that the co-treatment will significantly increase survival in the mutant mice 
compared to control treatment.  
 As a proof-of-concept experiment, we injected IDH1 wildtype glioma cells into mice and 
treated them with 1µM Panobinostat or gadolinium alone by CED. Mice were monitored by MRI 
for CED gadolinium distribution and showed good distribution (Figure 5.2A) and by IVIS for 
tumor growth (Figure 5.2B).  Only three mice were used for each group, but we found that 
Figure 5.1 Tazemetostat reduces H3K27me3 by CED in IDH1R132H glioma.  
 Mice were injected with IDH1R132H mutated glioma cells and treated with 350µM 
Tazemetostat by CED 30 days post-injection. Mice were sacrificed after 6 days and the tumor 
region was collected and lysed to measure epigenetic changes. A) Western blot of tumor brain 
homogenates of mice treated with Tazemetostat or vehicle. Homogenates were fractionated to 
the cytoplasmic fraction (CF) and the nuclear fraction was acid extracted (NF acid) B) 
Quantification of H3K27me3 normalized to H3. Fold change established using control mean. 




































Panobinostat significantly increased survival (Figure 5.2C). While these initial studies showed 
promising results suggesting that IDH1-wt gliomas are very sensitive to CED of Panobinostat, 
these results need to be confirmed with larger studies including more mice in each group. As 
seen by our in vitro studies, IDH1- wildtype glioma cells are more susceptible to Panobinostat 
treatment. We expect the IDH1R132H-mutant tumors to be less sensitive to Panobinostat than 




 We found that Tazemetostat and Panobinostat are synergistic and could be a promising 
treatment for patients with IDH1R132H gliomas. If our in vivo experiments show that 
Figure 5.2 Analysis of mice treated with gadolinium alone or Panobinostat by CED.  
 Mice were injected with IDH1 wildtype glioma cells and treated with gadolinium 
alone or 1µM Panobinostat for 7 days. Mice were monitored for moribundity. A) T2 and T1 
MRI of representative control and Panobinostat CED treated mice post-pump removal (28 
DPI). B) IVIS image of remaining alive mice 269 DPI with control on the left and 
Panobinostat treated on the right. C) Log-rank (Mantel-Cox) test chi square value is 5.052 and 






T1 T2 T1 T2
Control Panobinostat








































Tazemetostat and Panobinostat co-treatment increases overall survival in the IDH1R132H mouse 
glioma model, then we will then test the effects of co-treatment in acute slice cultures generated 
from human glioma surgical samples. We will determine if the human slices respond to the co-
treatment synergistically and with similar epigenetic changes seen in the mouse studies. 
Comparing the effect of Tazemetostat and Panobinostat (alone and in combination) in human 
slices generated from IDH-mut vs IDH-wt glioma samples would also allow us to test if IDH1-





Materials and Methods  
 
Retrovirus construction. PDGF-IRES-Cre was generated by cloning human PDGF-B 
and Cre into pQXIX vector (Clontech) as previously described59. IDH1R132H-IRES-CRE and 
PDGF-IRES-GFP retroviruses were generated by cloning the human IDH1R132H sequence and 
Cre or PDGF-B and GFP into the same vector. VSVG pseudotyped retrovirus was generated as 
previously described59. Briefly, 293GP2 cells were incubated with plasmids expressing VSVG 
and each viral plasmid mixed with CaCl2 and Hepes Buffered saline. Retroviruses were 
harvested and filtered, then re-suspended in PBS.    
Intracerebral stereotactic injections. Brain surgery procedures were done in adult 
mixed-background transgenic mice harboring floxed Trp53 and stop-floxed mCherry Luciferase 
(Thomas Ludwig, unpublished).  For subcortical white matter targeting, we used the coordinates 
of 2.0 mm lateral, 2.0 mm rostral and 2.0 mm deep, with bregma as the reference point. Using a 
stereotaxis platform, 1μl of the specified retrovirus was injected using a Hamilton syringe (flow 
rate 0.2μl/min) at a depth of 2mm. For serial transplantation experiments, 50×103 primary tumor 
cells were resuspended in Opti-MEM (Invitrogen) and injected at the same coordinate. All 
injections were done in mice between six and eight weeks of age. Overexpression of the PDGF-
BB mitogen combined with the deletion of the tumor suppressor gene, forms brain tumors with 
the histopathologic and molecular features of proneural glioblastomas. Tumor progression was 
monitored using Xenogen IVIS Spectrum imager 10-15 minutes after 100ul intraperitoneal 
injection of 30mg/ml luciferin (Caliper Life Sciences) with 1-minute exposure.  
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Primary OPC cultures. Primary mouse OPCs were isolated from the brain of floxed 
p53, stop-floxed mCherry Luciferase mice at postnatal day 5 through immunopanning with a rat 
anti-mouse CD140a antibody, recognizing PDGFRα, as previously described by Dr. Patrizia 
Casaccia’s laboratory52,263, and were cultured in a modified SATO medium (Dulbecco’s 
modified Eagle’s medium (DMEM), 4 μg/ml selenium, 5 mg/ml insulin, 1mM sodium pyruvate, 
2mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, B27 Supplement, N2 
supplement, Trace Element B, 10 μg/ml biotin) supplemented with PDGF-AA (20 ng/ml) and 
basic fibroblast growth factor (bFGF, 20 ng/ml). Trp53fl/fl OPCs were cultured as described 
above and then infected with an X-IRES-CRE or IDH1R132H-IRES-CRE retrovirus to obtain 
Trp53−/− OPCs and IDH1R132H Trp53−/− OPCs respectively.  
Primary tumor cell lines. Primary tumor cell lines were derived as described 
previously59,79,264. Once mice showed evidence of neurological features consistent with tumor 
morbidity, mice were sacrificed by cervical dislocation and decapitation. Brains were acutely 
harvested and maintained in prewarmed PBS (37°C). Tumors were surgically resected, minced in 
2.5% Trypsin and serially triturated by syringe using 18G and 21G needles. Triturated tumor 
tissue was filtered (70µm) then neutralized in 50% FBS and centrifuged at 1500rpm for 5 
minutes. Supernatant was discarded and tissue was cultured in defined tissue culture media 
containing high glucose DMEM (5.4g/L D-glucose, L-glutamine), 0.5% FBS, N2 Supplement, 
PDGF-AA (10 ng/ml), bFGF (10 ng/ml), and antibiotic–antimycotic solution. 
Slice culture. Once mice showed evidence of tumor growth by IVIS bioluminescence 
and neurological features consistent with tumor morbidity, mice were sacrificed by cervical 
dislocation and decapitation. Brains were harvested and incubated in ice-cold sucrose solution 
(210 mM sucrose, 10 mM glucose, 2.5 mM KCl, 1.25 mM NaH2PO4, 0.5 mM CaCl2, 7 mM 
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MgCl2 and 26 mM NaHCO3) for 30 minutes at 4 °C. Sections of 300 to 500 nm were cut using 
McIlwain Tissue Chopper and added to culture media (DMEM/F-12 supplemented with N2 and 
antibiotic-antimycotic solution) with drug treatment. After 1 hour of pretreatment, each 
individual slice was transferred to one Millicell cell culture insert (0.4uM, 30mm diameter) and 
cultured in drug treatments (DMSO, 50uM EPZ6438, or 200nM Panobinostat).  
Drug Treatment Cell Viability Assay. Cells were plated in black-walled 96-well plates 
and treated by serial drug dilution for 72 hours. CellTiter-Glo (Promega) was added to cells 
following manufacturer’s protocol. The luminescence was read on GloMax microplate reader 
(Promega) using provided manufacturer’s protocol.   
Whole cell lysis. Cells were washed with ice-cold PBS then scraped in Cell Extraction 
Buffer (Invitrogen) with freshly prepared protease inhibitor cocktail. Cells were moved to 
Eppendorf tubes and kept on ice for lysis. Tubes were sonicated every 10 minutes for 30 
minutes. Samples were spun at 13,000 rpm for 10 minutes at 4 °C and the lysate was transferred 
to new tubes and stored at -80 °C until use.  
Subcellular protein fractionation from cultured cells. Cells were lysed in hypotonic 
buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2,10 mM KCl) supplemented with 0.5 mM 
dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF), 5mM sodium butyrate, 
phosphatase inhibitor cocktail, and protease inhibitor cocktail freshly prepared (at 4 °C for 15 
min), followed by 0.5% NP40 treatment (vortex for 10 s) to disrupt the cell membranes. Lysates 
were then centrifuged at 1500 × g for 10 min at 4 °C to separate the cytoplasmic components 
(supernatant) from the nuclei-enriched fractions (pellets). Volumes (0.11uL/uL) of 10× 
cytoplasmic extraction buffer (0.3 M HEPES, 1.4 M KCl, and 30mM MgCl2) was added to the 
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supernatant and sonicated for 30 s ON/OFF for 5 min at high power in Bioruptor (Diagenode). 
After centrifugation at 16,000 × g for 10 min at 4 °C, the soluble fraction was collected as a 
cytoplasmic extract, and the pellet as the nuclear fraction.  
Differential centrifugation subcellular protein fractionation from brain homogenate. 
Tissue samples were homogenized in 50mM HEPES, 125mM NaCl, 0.1M sucrose with fresh 
protease inhibitor cocktail. Samples were spun for 10 minutes at 1000 x g at 4 °C and the 
supernatant was collected as the cytoplasmic fraction and the pellet as the nuclear fraction.  
Histone extraction and purification after fractionation. Histones were extracted from 
the nuclear fraction using the acid extraction method with all steps performed at 4 °C 265. The 
nuclear pellet was incubated for 1.5 hours to overnight in 0.4 N H2SO4. After centrifugation at 
16,000 x g for 10 min, nuclear debris were removed, and acid-soluble histones were then 
precipitated using trichloroacetic acid for at least 30 minutes. Samples were spun for 10 minutes 
16,000 x g and washed twice in acetone then re-suspended in water. 
Immunofluorescence and immunohistochemistry. Cells for immunofluorescence were 
washed with PBS then fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature 
and then the membrane was permeabilized and blocked with 0.5% (vol/vol) Triton X-100 (Fisher 
Scientific) and 5% normal goat serum for 1 hour. Primary antibodies were applied overnight at 4 
°C followed by incubation of appropriate secondary antibodies conjugated with fluorophores. 
Images were captured using Nikon TE2000 epifluorescence microscope equipped with 
MetaMorph software (Version. V.7.6.5.0, Molecular Devices). Quantification of the 
immunofluorescent intensity was done using ImageJ. Tumor bearing mice were anesthetized and 
perfused with 4% PFA. After tissue processing and paraffin embedding, sections of 5 μm were 
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cut sectioned by the Columbia University Medical Center Molecular Pathology Shared Resource 
facility. To perform immunohistochemistry, sections were de-paraffinized, immersed in 10 mM 
citrate buffer, pH 6.0, for 10 min in the microwave at 650 W, followed by blocking with 10% 
normal goat serum, before overnight incubation of primary antibodies at 4 °C. Appropriate 
secondary antibodies conjugated with fluorophores were used the following day to complete the 
staining. DAPI (4′,6-diamidino-2phenylindole) was used as a nuclear counterstain.  
Microscopy. Stained tissue sections and fluorescent reporters of labeled tumor-derived 
cells were imaged using a Nikon TE2000 epifluorescence microscope equipped with MetaMorph 
software (Version. V.7.6.5.0, Molecular Devices). Micrographs were processed and merged 
using MetaMorph and ImageJ.  
Cellular Dissociation for Flow Cytometry. Slice culture and brain tumors were 
dissociated using filtered Carica Papain extract diluted 1:20 in 1N NaOH PBS (supplemented 
with 2mg/mL L-cysteine) for 30 minutes at 37°C with shaking then centrifuged in excess PBS at 
400xg for 5 minutes. The slices were manually dissociated with a pipette then sucrose was added 
(final 15%) and the samples were spun at 1000 rpm for 5 minutes to remove debris. The 
remaining bottom ~30% was washed in PBS then processed for flow cytometry.   
Flow cytometry. Cells were collected and fixed with 4% formaldehyde (methanol-free) 
for 15 minutes at room temperature. Cells were centrifuged in excess PBS 400 x g for 5 minutes 
for all washes. Cells were permeabilized by adding 100% ice-cold methanol drop-wise while 
gently vortexing cells to a final concentration of 90% methanol. Cells were incubated on ice for 
30 minutes then washed in excess PBS to remove methanol. Cells were resuspended in diluted 
primary antibodies and incubated for 1 hour at room temperature. They were washed in excess 
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PBS and then resuspended in diluted fluorochrome-conjugated secondary antibodies and 
incubated for 30 minutes at room temperature. Cells were washed again in excess PBS then 
resuspended in PBS for flow cytometry reading. The BD LSRFortessa was used for optical 
measurements and analysis was performed by FlowJo version 9 (Ashland, OR: Becton, 
Dickinson and Company; 2019). 
RNA extraction and sequencing. Total mRNA was extracted using the Qiagen RNeasy 
Mini kit (Qiagen, 74106). The Columbia Sulzberger Genome Center sequenced the RNA 
samples (mm10, Illumina iGenomes) and Tophat2 was used to map the reads. Differential 
expression analysis was performed using Cuffdiff2. The Verhaak glioma classification data set6 
was used to determine glioma subtypes. We used expression data from the murine brain 
transcriptome database11 to create cell type specific gene sets with the top 200 enriched genes, 
based on fold change above average expression, found in astrocytes, oligodendrocytes, neurons, 
OPCs, newly formed oligodendrocytes, myelinating oligodendrocytes, microglia, and endothelia. 
We performed Gene Set Enrichment Analysis195 on the RNA sequencing data using on these 
cell-type-specific gene sets.  
Metabolite Analysis. Cells were washed 2X with cold PBS in 10cm dishes then scraped 
with 1ml 80% methanol (-80°C) on dry ice. Cells were vortexed for 1 minute then incubated on 
dry ice for 5 minutes and then vortexed again for 1 minute. The cells were centrifuged for 
14,000rfc for 20 minutes at 4 °C then transferred to a clean tube and stored at -80°C until 
analysis. The Weill Cornell Medicine Proteomics & Metabolomics Core Facility analyzed the 
samples. Metabolite pathways were analyzed by MetaboAnalyst 4.0 10.  
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Statistical Analysis and Graphing. All graphs with statistical analysis were made in 
Graphpad Prism version 8.0.0 for Mac, GraphPad Software, San Diego, California USA, 
www.graphpad.com. All volcano plots and statistical analysis were made using R Core Team 
(2020). R: A language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria, www.R-project.org. Heatmaps were made using R or Multi-experiment 
viewer (MeV) version 10.2 266. Western blots were analyzed and quantified using Image Studio 
Lite analysis software V. 5.2 (LI-COR Biosciences).   
Chromatin Immunoprecipitation. Cells were harvested and crosslinked using 1% 
formaldehyde for 10 minutes on shaking platform. Crosslinking was stopped by adding glycine 
to a final concentration of 0.125M and incubated for 5 minutes on shaking platform. Samples 
were centrifuged for 5 minutes at 500xg (4°C) and the supernatant was discarded. Cells were 
washed twice with ice-cold PBS and spun at 500xg for 5 minutes (4°C). Cells were resuspended 
in 10ml ice-cold Covaris lysis buffer (50mM Hepes-KOH pH 7.5, 140mM NaCl, 1mM EDTA 
pH 8.0, 10% glycerol, 0.25% Triton X-100, 0.5% NP40 and freshly-added protease inhibitors) 
and incubated with rotation for 10 minutes at 4°C. Samples were centrifuged for 5 minutes at 
4000 rpm (4°C) to pellet nuclei. Nuclear pellet washed in 10ml ice-cold Covaris wash buffer 
(10mM Tris-HCl pH 8.0, 200mM NaCl, 1mM EDTA pH 8.0, 0.5mM EGTA pH 8.0, and freshly 
added protease inhibitors) with rotation for 10 minutes at 4°C. Samples were centrifuged for 5 
minutes at 4000 rpm (4°C).  Nuclei resuspended in ice-cold Agilent sonication buffer (10mM 
Tris-HCl pH 8.0, 100mM NaCl, 1mM EDTA pH 8.0, 0.5mM EGTA pH 8.0, 0.5% N-
lauroylsarcosine Sodium Salt, freshly prepared Na-deoxycholate (0.1%) and freshly added 
protease inhibitors) at 10-20x106 cells/ml. Samples were sonicated 30 s ON/OFF for 15 min at 
high power at 4°C in Bioruptor (Diagenode). TritonX-100 was added to 1% final concentration. 
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50ul of sonicated chromatin saved as input and stored at 4°C. The appropriate antibody was 
added to each IP and incubated overnight at 4°C with rotation. Protein G magnetic beads 
(100µL) were washed three times in 1 ml of ice-cold blocking buffer (0.5% BSA in PBS) by 
inverting the tubes several times and collecting beads using a pre-cooled magnetic rack. 
Chromatin bound to antibody was added to washed beads and incubated on rotating platform for 
4-5 hours at 4°C. Supernatant removed from beads using pre-cooled magnetic stand. Beads 
washed twice with 1 mL of ice-cold sonication buffer with 1% TritonX-100 and incubated with 
rotation for 5 minutes (4°C). Supernatant was removed using pre-cooled magnetic stand and 
beads were washed twice with Wash Buffer A (50mM Hepes pH 7.8, 500mM NaCl, 1mM 
EDTA, 1% Triton X-100, 0.1% freshly prepared Na-deoxycholate, freshly added 0.1% SDS and 
protease inhibitors) by incubating with rotation for 5 minutes (4°C). Supernatant was removed 
using pre-cooled magnetic stand and beads were washed twice with Wash Buffer B (20mM Tris-
HCl pH 8.0, 250mM LiCl, 1mM EDTA, 0.5% NP40, 0.1% freshly prepared Na-deoxycholate, 
freshly added 0.1% SDS and protease inhibitors) by incubating with rotation for 5 minutes (4°C). 
Supernatant was removed using pre-cooled magnetic stand and beads were washed twice with 
TE buffer (pH 8.0) with 50mM NaCl by incubating with rotation for 10 minutes (4°C).The 
supernatant was removed using pre-cooled magnetic stand and 210µL of elution buffer (50mM 
Tris-HCl pH 8.0, 10mM EDTA, and freshly added 1% SDS) was added to beads. Beads were 
delicately vortexed and incubated for 16 minutes at 65°C with delicate vortexing every 2 
minutes. Samples were centrifuged for 2 minutes at 10,000 rpm (RT) and the supernatant was 
recovered. The IPs and input were incubated in 65°C overnight to reverse the crosslinking. 
RNAse A (40 µg molecular grade) was added and incubated for at least 2 hours at 37°C. 
 95 
Proteinase K (80 µg) was added and incubated for 30 minutes at 55°C. DNA was cleaned using 
MicroChIP DiaPure columns (Diagenode).  
Quantitative PCR. qPCR was performed using Absolute Blue QPCR Mix, SYBR 
Green, low ROX (Thermo Scientific). All qPCR conducted at 95°C for 15 minutes, then 40 
cycles of 95°C for 15s, 60°C for 30s, and 72°C for 30s. The specificity of the reaction was 
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Appendix A: The Effects of Metabolic Stress on Epigenetic Marks in 
Low Grade Glioma Cells 
 
Low grade gliomas are diffusely infiltrating brain tumors that intermingle with non-tumor 
cells. Cell growth requires nutrients, energy, and biosynthetic activity for necessary cellular 
components during cell cycle progression. Cancer cells exhibit unchecked proliferation and thus 
have profoundly different metabolic activity compared to normal cells. Reactive oxygen species 
(ROS) are produced at low levels during the electron transport chain during normal cellular 
metabolism and play a role in proliferation, differentiation and cell signaling regulation 267. 
Metabolic stress occurs from either lack or excess of nutrients which produces excess ROS that 
is non-physiological. Oxidative stress can cause DNA mutations, inflammation, inhibition of 
protein tyrosine phosphatases, Hypoxia-Inducible Factor (HIF) activation, and even cell death 
and damage to cellular components 267.   
ROS also have been shown to cause epigenetic changes. JmjC domain-containing histone 
demethylases regulate gene expression by removing lysine methylation. JmjC domain uses 
alpha-ketoglutarate and Fe(II) as cofactors in oxidative demethylation. ROS is thought to oxidize 
Fe(II) to Fe(III) and therefore inhibit these demethylases 268. Histone H3 Lysine 27 (H3K27) is 
demethylated by UTX/KDM6A and JMJD3/KDM6B. They are members of the KDM6 family of 
demethylases and are JmjC domain-containing. Specifically UTX/KDM6A, has high oxygen 
affinity, is able to directly sense oxygen, and ROS diminished its activity 268.  
EZH2 is the main writer for H3K27 trimethylation. EZH2 plays an essential role in stem 
cell renewal, maintenance, and cell lineage differentiation by repressing specific genes 268. It is 
thought that EZH2 promotes cellular transformation by blocking differentiation 269. EZH2 
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overexpression and gain-of-function mutations have been identified in multiple different cancer 
types including glioma 136. Similarly, loss-of-function mutations affecting UTX occur in several 
human cancers that cause increased levels of H3k27 trimethylation 136. The EZH2 inhibitor 
Tazemetostat reduces H3K27me3 and has been approved for treating specific types of cancers. 
EZH2 inhibitors remove the repressive mark and allow for specific genes to be expressed.  
A.1 Results 
 The Canoll lab previously created a mouse model of low-grade glioma using cre-
expressing retroviruses to deliver transforming genetic alterations to OPCs in the adult 
subcortical white matter of transgenic mice 59,66,69,270. Our lab formerly used the RiboTag system 
with PDGFB-expressing retroviral injections to compare ribosome profiles of tumor-induced 
mice with normal mouse brains 271.  EZH2 was significantly enriched in the tumor homogenate 
suggesting increased expression in our mouse glioma models. We hypothesize that EZH2 causes 
epigenetic changes in tumors that promote gliomagenesis. EZH2 inhibitors could help treat 
cancer both at the tumor cell and microenvironmental level.  
 Based on the increase of EZH2 expression on transformed cells, we used the EZH2 
inhibitor Tazemetostat (EPZ-6438) to determine cytotoxicity and epigenetic changes. It has been 
found that various tumor models have different EZH2 inhibitor sensitivities198 so we first wanted 
to see if our tumor model was sensitive. We found that our low-grade glioma model, in which 
PDGFA is overexpressed and TP53 is deleted, was insensitive to Tazemetostat (Figure A. 1A) 
with no effect on cell growth with doses up to 30µM, although it was found to be effective in 
reducing H3K27me3 at doses as low as 0.03µM (Figure A. 1B). Tazemetostat is dose dependent 
but is not cytotoxic in this model.  
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 We next wanted to see if the effect of Tazemetostat was time-dependent (Figure A. 2A). 
Interestingly, when looking at whole cell lysates we did not see any H3K27me3 at the 24-hour 
timepoint but increasing levels of trimethylation as time progressed. Tazemetostat prevents 
H3K27me3 but at 72-hours there appears to be some inhibitor escape. Culturing glioma cells 
under conditions of metabolic stress (leaving them in media for 72-hours) increased H3K27 
trimethylation.  
 To determine if this increase of trimethylation was due to changes in the media that occur 
while culturing cells overtime, cells were treated with conditioned media. This media was 
collected from cultured cells and then added to newly plated cells for 2, 24, 48, or 72 hours 
compared to cells cultured in new media (Figure A. 2B). Treating cells with cultured media 
increased trimethylation after 24 and 48 hours. At 72-hours there appears to be a reduction of 
H3K27me3, but this is probably due to the media becoming toxic to the cells and we saw some 
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Figure A. 1 Tazemetostat reduced H3K27me3 without cytotoxicity.  
A) MTS assay of cells treated with increasing doses of Tazemetostat for 3 days. B) 
Western blot of whole cell lysate showing decreasing levels of H3K27me3 with increasing 
doses of Tazemetostat after 72 hours.  
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cell death. This suggests that some change in the media causes metabolic stress which increases 
H3K27me3 as cultured media alone caused the induction.  
 To make sure this metabolic stress was due to changes in the culture media and not to 
cellular contact or some other mechanism, we changed the media every day. As we cultured the 
cells they became more confluent, which could also increase metabolic stress and trimethylation. 
When cells were cultured for 96 hours and the media changed every day (D), H3K27me3 was 
undetectable, but when media was left there was increased trimethylation (Figure A. 2C). By 
changing the media, H3K27me3 was reduced. This suggests that something, either being added 
to the media or removed, induces trimethylation, which shows that culture conditions induce 
H3K27me3.  
 
 To further establish what other metabolic stresses induce H3K27 trimethylation, we 
deprived cells of specific nutrients usually present in basal cell culture media. Cells were 
cultured in either conditioned med (CM) or growth-factor-free media (GFF) for 48 and 72 hours 
Figure A. 2 Culture media conditions induce increases in H3K27me3 which are blocked by 
Tazemetostat.  
A) Western blot showing time course of cells being cultured in regular media and in 
3µM Tazemetostat (EZH2i). Culturing cells over time induces H3K27me3 but Tazemetostat 
blocks trimethylation. B) Western blot showing time course of cells treated with conditioned 
media collected from other cultured cells. Conditioned media induced H3K27me3. C) 
Western blot of cells treated with Tazemetostat (EZH2i), having their media changed every 
day (D) or left for 72 hours and 96 hours.  
EZH2 inhibitor prevents stress induced 
H3K27me3
24h 48h
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(Figure A. 3A). Both conditioned media and growth-factor-free media stimulated H3K27me3. 
One possibility is that conditioned media has reduced amounts of growth factors which induces 
H3K27me3 in glioma cells.  
 
 To determine if ROS causes the increase of H3K27me3, cells were treated with b-
mercaptoethanol (BME). b-mercaptoethanol is an antioxidant that scavenges hydroxyl radicals. 
Glioma cells in growth factor free media have increased H3K27me3 however b-mercaptoethanol 
partially blocked trimethylation (Figure A. 3B).  Tazemetostat almost completely removes 
H3K27me3. b-mercaptoethanol could be less effective due to dose and timing. H3K27me3 is 
demethylated by UTX/KDM6A and JMJD3/KDM6B which are Fe(II) and a-ketoglutaric 
dependent dioxygenases. It is thought that these dioxygenases can be inhibited by ROS 272. 
Figure A. 3 Growth factor depletion and ROS production induce H3K27me3.  
 A) Western blot of glioma cells treated with conditioned media (CM) or growth factor 
free media (GFF) for 48 and 72 hours.  B) Western blot of cells cultured in growth factor free 
media treated with b-mercaptoethanol (BME) or 3µM Tazemetostat (EZH2i) for 72 hours. C) 
Western blot of glioma cells in basal media with growth factors treated with b-
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Growth-factor-free media metabolically stresses glioma cells and causes the production of ROS 
which is blocked by b-mercaptoethanol.   
 The decrease of H3K27me3 after b-mercaptoethanol treatment suggests that even in 
competent media with growth factors, b-mercaptoethanol could still block trimethylation. 
Glioma cells were left in culture for 72 hours to stress the cells and treated with b-
mercaptoethanol or Tazemetostat (Figure A. 3C).  EZH2 inhibition blocked H3K27me3 as 
expected. b-mercaptoethanol also reduced trimethylation levels, suggesting that culturing the 
cells for 72 hours increases H3K27me3, at least in part via ROS-induced mechanisms. One 
possibility is that the increased ROS production blocks UTX/KDM6A and JMJD3/KDM6B 
demethylases, which results in increased H3K27 trimethylation levels.  To further explore this 
hypothesis, we will treat cells with ROS-inducing substances (such as hydrogen peroxide) to see 
if increased ROS induces H3K27me3. 
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Figure A. 4 Glucose-free media induces H3K27me3 in glioma cells.  
A) Western blot of glioma cells cultured for 2, 24 and 48 hours with or without 
glucose. B) Western blot of cells cultured in glucose-free media with or without 3µM 
Tazemetostat (EZH2i) for 2, 24 and 48 hours. C) Western blot comparing glioma cells 
cultured in basal media to low glucose (1g/L) media with or without 3µM Tazemetostat 
(EZH2i) for 48 hours.  
 123 
 To determine what other nutrients in cell culture media influence H2K27 trimethylation, 
we deprived glioma cells of glucose. Glucose is necessary for cellular energy and to neutralize 
oxidative stress. Glucose deprivation has been shown to increase ROS levels 273. Cells were 
cultured in media with glucose or deprived of glucose (Figure A. 4A). When cells were cultured 
without glucose for 48 hours, they show a marked increase of H3K27me3 compared to cells 
cultured with glucose. To determine if EZH2 inhibition reduces glucose-deprivation-induced 
H3K27me3, cells were treated with Tazemetostat. Treating cells with Tazemetostat prevented 
H3K27 trimethylation (Figure A. 4B). After 48 hours in glucose-free media the cells started to 
die. To make sure the increase of trimethylation was due to glucose deprivation and not cell 
death, cells were cultured in media with low glucose to stress the cells without as much toxicity. 
Our glioma cells are normally cultured in high glucose media (4.5g/L) but other cell types are 
commonly cultured in lower glucose concentrations. When glucose concentration was reduced, 
cells did not die after 48 hours but did increase their levels of H3K27me3 (Figure A. 4C). 
Stressing glioma cells by glucose deprivation or reduction causes increased H3K27 
trimethylation independent of the cytotoxic effects.      
A.2 Discussion  
 EZH2 is overexpressed in multiple different types of cancers. We found that in our 
murine model of proneural glioma, EZH2 is overexpressed in the tumor cell. This suggests that 
EZH2 promotes gliomagenesis by increasing the repressive mark, H3K27me3.  
 We treated cells with Tazemetostat to reduce H3K27me3 and change gene expression. 
Notably, Tazemetostat is not cytotoxic in our low-grade tumor model but the drug still reduced 
trimethylation levels (Figure A. 1). Other groups have shown that some cancers are insensitive to 
EZH2 inhibition 198. We hypothesize that although our cells are insensitive to Tazemetostat, 
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treatment could sensitize glioma cells to other drugs (such as HDAC inhibitors).  This leads to 
the therapeutic hypothesis that was explored in chapters 3 and 4. 
 Interestingly, we found that cell culture conditions that induce metabolic stress led to 
increased levels of H3K27 trimethylation, and that Tazemetostat blocked it. By leaving cells in 
culture without changing their media or by treating them with conditioned media (Figure A. 2), 
we were able to induce trimethylation. This suggests either that something is being added to the 
media (such as lactic acid or cytokines) that induce H3K27me3 or that the cells are using up 
something in the media (such as glucose or growth factors) and the deprivation induces 
H3K27me3.  
 To better understand the metabolic-stress-induced H3K27me3, we changed culture 
conditions. We found that growth factor and glucose deprivation induced H3K27me3 and that 
EZH2 inhibition blocked this induction (Figure A. 3/Figure A. 4). Interestingly, treating cells 
with an antioxidant (b-mercaptoethanol) diminished H3K27me3. This leads us to our hypothesis 
that metabolic stress increases ROS, which blocks H3K27me3 demethylases. This is important in 
cancer progression as ROS can facilitate cellular transformation. Our data suggest that ROS 
could cause increased H3K27me3, which promotes gliomagenesis by keeping cells more 
lineage-restricted.  IDH1R132H-mutated glioma cells exhibit increased ROS production 274,275.  
We found in Chapter 2 that IDH1R132H cells have increased levels of H3K27me3 compared to 
wildtype which could be due to ROS production as well as 2HG. To try to reduce ROS 
production I used shorter time-courses (48 hours) when comparing H3K27me3 levels.    
 It is of importance to note that all Western Blots in this chapter were conducted using 
whole-cell extract. We were able to look at multiple protein compartments (cytoplasmic, nuclear, 
and histones) but protein concentrations were also measured as a total. This method uses total 
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protein amount for lane normalization and does not control for total histone levels which is 
shown by inconsistent total H3. In all other chapters, cells were fractionated then histones were 
acid extracted for consistent protein levels for each compartment. For future experiments looking 
at epigenetic changes due to metabolic stress, cells will be fractionated then acid extracted.  
 
